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RÉSUMÉ 
Connue pour son rôle dans la cascade de coagulation, la thrombine, une protéase à 
sérine, peut également agir par l’intermédiaire de PAR1, un récepteur activé par protéase et 
couplé aux protéines G liant le GTP (GPCR). La thrombine se lie et clive l’extrémité N-
terminale du PAR1 entre l’Arg41 et la Ser42, exposant une nouvelle extrémité terminale qui agit 
elle-même comme un ligand. La thrombine et une séquence peptidique de cinq acides aminés, 
composée des résidus Ser
42
 à Arg
46
, nommée PAR1-AP, déclenchent dans diverses cellules de 
mammifères une réponse intracellulaire comportant une composante calcique. 
Dans cette étude, le système d’expression par baculovirus dans les cellules Sf9 
d'insecte nous a permis d'exprimer le récepteur PAR1 du rat à la surface de ces cellules et de 
réaliser son couplage fonctionnel à leur signalisation intracellulaire (modèle rPAR1-Sf9). La 
composante calcique de celle-ci, en réponse au PAR1-AP,  a ensuite été étudiée en détail à 
l’aide de la sonde fluorescente Fura-2 et de plusieurs inhibiteurs agissant sur les canaux 
calciques ou d'autres éléments de la cascade de signalisation du calcium intracellulaire. 
Lorsque le milieu extracellulaire contient du calcium (Ca
2+
), la thrombine ou PAR1-
AP déclenchent un signal calcique qui consiste en une augmentation rapide de [Ca
2+
]i suivi 
d’un plateau relativement soutenu, puis d'un retour lent vers le niveau de base initial. En 
l'absence de Ca
2+
 dans le milieu extracellulaire, l'augmentation initiale rapide de [Ca
2+
]i est 
suivie d'un retour rapide vers le [Ca
2+
]i de base. 
À l’aide d’inhibiteurs de canaux calciques, tels que le lanthane, la nifédipine et le D-
600, l'entrée du calcium du milieu extracellulaire dans les cellules est inhibée, abolissant le 
plateau soutenu de [Ca
2+
]i. L’inhibition de la pompe Ca
2+
-ATPase par la thapsigargine 
supprime la réponse au PAR1-AP après épuisement des sites de stockage de 
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Ca
2+
intracellulaire.  Le TMB-8 agit de façon discordante quant à l’inhibition de la libération 
de Ca
2+
 des sites de stockage intracellulaires.  La réponse à PAR1-AP n’est pas affectée par le 
D-609, un inhibiteur de la phospholipase β.  L’inhibition de la protéine kinase C (PKC) par le 
bisindolylmaléimide induit des oscillations en présence de Ca
2+
 extracellulaire et atténue 
fortement le signal calcique en absence de Ca
2+
 extracellulaire.  En présence de Ca
2+ 
extracellulaire, l’activation de la PKC par le PBDu tronque le flux de [Ca2+]i tandis que la 
réponse calcique est abolie en absence de Ca
2+ 
dans le milieu extracellulaire. Le H-89, un 
inhibiteur de la protéine kinase A (PKA), cause une prolongation de la durée du plateau de 
[Ca
2+
]i dans un milieu riche en calcium et la suppression de la réponse à PAR1-AP lorsque le 
milieu extracellulaire est dépourvu de Ca
2+
.  
Les résultats obtenus nous permettent de conclure que la PKC et possiblement la PKA 
jouent un rôle critique dans la mobilisation du Ca
2+
 induite par le PAR1-AP dans le modèle 
rPAR1-Sf9. 
 
Mots clés: cellule Sf9, baculovirus, thrombine, récepteur activé par protéase (PAR), 
signalisation calcique, canal calcique, Fura-2
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ABSTRACT 
 Thrombin’s serine protease activity allows for it to have a role in both the coagulation 
cascade as well as through a GTP- binding protein coupled receptor (GPCR) known as the 
protease-activated receptor-1 (PAR1). Thrombin binds to PAR1 at the N-terminal, cleaving 
between Arg
41
 and Ser
42
, and unmasking a new N-terminal which acts as a tethered ligand. 
Thrombin and a five amino acid peptide composed of the sequence of residues Ser
42
 to Arg
46
, 
known as PAR 1-AP, has been shown to mediate a number of signalling mechanisms in 
mammalian cells, including a calcium signalling pathway.   
 In the present study, the Sf9-baculovirus system allowed us to express the rat PAR1 
(rPAR1-Sf9) on the cell surface and study its intracellular signalling.  The calcium (Ca
2+
) 
signal was studied using the fluorescent probe Fura-2, and several Ca
2+ 
channel inhibitors and 
calcium signal modulators were used to study the signal induced by PAR1-AP.   
 In the presence of extracellular calcium
 
[Ca
2+
]e, thrombin and PAR1-AP produced a 
Ca
2+
 signal which consisted of an initial spike in [Ca
2+
]i followed by a relatively maintained 
plateau and a slow return towards baseline.  In the absence of Ca
2+
 in the extracellular space, 
the initial Ca
2+
 increase is followed by a quick return to baseline [Ca
2+
]i. 
 Ca
2+
 channel inhibitors, lanthanum, nifedipine and D-600, inhibited the entry of Ca
2+
 
from the extracellular space and abolished the plateau phase of the response to PAR1-AP. 
Inhibition of the Ca
2+
-ATPase with thapsigargin abolished the response to PAR1-AP after 
having depleted the Ca
2+
 stores involved in the initial spike in [Ca
2+
]i. TMB-8, expected to 
inhibit the release of Ca
2+
 from internal stores, inconsistently inhibited the [Ca
2+
]i  response to 
PAR1-AP. The response elicited by PAR1-AP was not affected by D-609, an inhibitor of 
phospholipase Cβ. Inhibition of protein kinase C (PKC) with bisindolylmaleimide induced 
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oscillations in the [Ca
2+
]i levels in the presence of extracellular Ca
2+
 while it significantly 
blunted the response in the absence of extracellular Ca
2+
. PDBu activation of PKC truncated 
the [Ca
2+
]i surge in Ca
2+
-rich conditions while abolishing it altogether in the absence of 
extracellular Ca
2+
.  H-89 inhibition of protein kinase A (PKA) prolonged the plateau duration 
in Ca
2+
-rich medium while inhibiting the response to PAR1-AP in a Ca
2+
-deficient 
environment.  
 Taken together, our results suggest that PKC and possibly PKA play a critical role in 
the mobilisation of Ca
2+
 in rPAR1-Sf9 by PAR1-AP. 
  
Key words: Sf9, baculovirus, thrombin, protease-activated receptor (PAR), calcium signalling, 
calcium channel, Fura-2.
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INTRODUCTION 
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 Thrombin is a well-studied protein of the coagulation cascade. Its proteolytic activity 
has long interested cardiovascular physiologists, due to its critical involvement in the 
formation of platelet plugs and subsequent clot formation. The proteolytic cleavage of 
fibrinogen to fibrin, by thrombin, is a critical step in clot stabilization.  It is now known that 
thrombin’s actions go well beyond the cleavage of fibrinogen. Thrombin is involved in the 
pathophysiology of thrombosis, and in other processes including atherosclerosis [1], and even 
tumor growth [2].   
By studying thrombin’s effects on different functional systems, investigators identified 
the thrombin receptor [3] as part of a unique subclass of G-protein coupled receptor (GPCR), 
activated through proteolytic cleavage of the extracellular domain. The subclass is known as 
the protease activated receptors (PARs).  While thrombin’s serine protease action is a critical 
component of the coagulation cascase, activation of its receptor, the protease activated 
receptor-1 (PAR1), mediates much of thrombin’s cellular activity [2, 4-7]. 
1.1 Coagulation cascade 
 
 The coagulation cascade is integral to maintaining homeostasis and is divided into an 
intrinsic and an extrinsic system.   
The intrinsic pathway, is activated by the exposure of subendothelial collagen, platelet 
phospholipids and the presence of ionized calcium and plays a secondary role in coagulation.   
The extrinsic system is the principal pathway of blood coagulation.  It involves both 
vascular and blood elements. Vascular injury damages endothelial cells and exposes tissue 
factor; a glycoprotein embedded in and around blood vessels and various other tissue cells.  
Tissue factor contributes to the activation of the extrinsic pathway of the coagulation cascade, 
which begins with an inactive form of Factor VII. A series of steps ensues whereby each 
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coagulation factor is activated by its predecessor [8], with the exception of those factors that 
are involved in the common pathway. 
Lastly, blood components, in particular, leukocyte and monocyte derived 
microparticles, can be recruited to sites of vascular injury, and express low levels of tissue 
factor as well, thus play a role in activating the coagulation cascade. 
The common pathway refers to the final steps of the coagulation cascade common to 
both the intrinsic and extrinsic systems and consists of the activation of Factor X to form 
Factor Xa. This critical step is required for the cleavage of thrombin from its precursor state, 
prothrombin [9].  
Thrombin is ultimately required for the cleavage of fibrinogen into fibrin through its 
serine protease activity.  This final step in the coagulation cascade is responsible for clot 
stabilization and solidification [9].  
1.2 Thrombin and its receptor 
 
1.2.1 Thrombin 
 
 While thrombin is best known for its role in the circulatory system, it has also been 
identified as being involved in a multitude of different physiological systems including the 
vascular, respiratory, gastrointestinal, renal, musculoskeletal and nervous systems [6].   
Within the circulatory system, inappropriate activation of thrombin leads to the 
formation of thrombi.  These circulating blood clots may partially or fully occlude blood 
vessels, causing thrombosis, stroke or cardiac ischemia. 
Thrombin’s structure consists of a globular protein (Figure 1A), composed of two 
chains which are 36 and 259 amino acids in length and linked by a single disulfide bond.  It is 
 4 
 
ellipsoid in shape and interacts with its substrates in a highly specific manner [7]. The 
structural details of this interaction are shown in Figure 1B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Thrombin’s molecular structure. A: Thrombin structure. Thrombin’s active site 
is flanked by three catalytic amino acids (His
43
, Asp
99
, Ser
205
) at its base.  This triad is 
surrounded by the primary specificity pocket (Asp
109
) and two insertion loops [10].Two anion 
binding exosites are located at the extremities of the molecule and are responsible for 
thrombin’s actions. Anion exosite 1 recognizes fibrinogen and the N-terminal of PAR1, while 
exosite 2 is involved in the interaction with heparin [11]. B: Thrombin–PAR1 interface. The 
hydrophobic regions of thrombin are coloured in orange and its polar regions are light blue. 
Thrombin’s residues involved in contact with PAR1 sit in the hydrophobic region with black 
labels representing thrombin’s residues and red labels representing the residues located on 
PAR1. The residues involved in the cleavage of the extracellular fragment of PAR1 have been 
labelled in red.  The N-terminal of PAR1 fits into exosite 1 through polar and hydrophobic 
interactions. Hydrogen bonds which form between thrombin and PAR1 are depicted as broken 
lines [10]. (Adapted from [10]) 
 
 
1.2.2 Protease-activated receptor 1 (PAR1) 
 
In addition to its role in the coagulation cascade, thrombin exerts its receptor-specific 
activity through PAR1 [6]. The PAR1 receptor is a member of the GPCR receptor 
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superfamily. The three-dimensional structure of the human PAR1 crystalized in the presence 
of vorapaxar, a PAR1 antagonist, has recently been elucidated [12] and is shown in Figure 2.  
 
 
 
Figure 2:  Structure of human PAR1 with an 
antagonist.  The overall structure of PAR 1 is 
shown with transmembrane helices labelled TM2-
7. Extracellular loop 2 (ECL2) and the N-terminal 
(N) of the receptor are critical components of the 
receptor activation by the tethered ligand. Orange 
sticks represent lipid molecules required for 
crystallogenesis technique and may not be present 
in actual physiological conditions. The antagonist 
(vorapaxar) is represented in green. (Adapted from 
[13]) 
 
 
 
 
 
The protein is 425 amino acids long, and is organized into seven helical 
transmembrane domains with three intracellular and three extracellular loops (Figure 2 and 
Figure 3A).  The N-terminal of the receptor is extracellular. This exodomain contains the 
thrombin cleavage site and the region that will form the new ligand after cleavage. Figure 3B 
shows the primary sequences of the human, mouse, hamster and rat PAR1 exodomains, as 
well as the tethered ligand sequences, the thrombin interaction sites and the ligand binding 
sites.  They display a high level of homology.  The C-terminal of PAR1 is located 
intracellularly and possesses a large number of serine and threonine residues.  
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Figure 3: A: PAR1 sequence. The amino acid sequence includes the thrombin cleavage site, 
the extracellular domain, extracellular loops (ECL) and cytoplasmic loops (CL). Intracellular 
phosphorylation sites appear in red letters. Pink boxes include the extracellular domains where 
the newly cleaved N-terminal interacts with the ligand binding site-1 (located in the N-
terminal exodomain above) and extracellular loop 2 (ECL2). (Adapted from [14]) B. PAR1 
exodomain sequences in various species. Considerable sequence homology exists in PAR1 
exodomains across species. Thrombin molecules interact with the receptor through thrombin 
interaction sites 1 and 2.  Cleavage of the peptide bond between Arg
41
 and Ser
42
 yields a new 
N-terminal.  The peptide sequence located at the new N-terminal is referred to as the tethered 
ligand sequence. The receptor’s N-terminal binds at ligand binding site-1 to activate 
downstream signalling. (Adapted from [15])   
 
Thrombin activates its receptor through a highly specific (Km of 15-30 M) proteolytic 
cleavage at a site located between residues Arg
41
 and Ser
42
 (Figure 3) [15-17]. Thrombin’s 
receptor mediated activity depends on its ability to bind to the PAR1 receptor’s N-terminal 
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exodomain (Figure 4) and cleave a peptide bond between Arg
41
 and Ser
42
, yielding a new N-
terminal [9].  
  Receptor activation occurs through two thrombin interaction sites on the receptor; the 
first immediately N-terminal to Arg
41
 and the second between residues 53 (responsible for the 
recognition of the receptors’ cleavage site) and 64 (involved in an interaction with one of the 
anion binding exosites on thrombin). PAR1 requires interaction of the Arg-Asp-Pro-Leu 
segment with the apolar pocket of the thrombin molecule [18].  In the interaction of thrombin 
with its receptor, an initial contact is made between exosite-1 (Figure 4) on thrombin and the 
receptor’s thrombin interaction site-1 (Figure 3B).  The N-terminal then becomes newly 
oriented, and a hydrogen bond between Asp
39
 and Arg
41
 is disrupted, freeing the arginine and 
allowing cleavage of the receptor to occur through thrombin’s active site (Figure 3) [14, 15]. 
Cleavage creates a new, tethered, N-terminal sequence starting after Arg
41
, which binds to the 
ligand binding site-1 [15]  located within the N-terminal exodomain [19].  Although 
extracellular loop 2 is the main site for binding of the tethered ligand (Figure 3A), binding also 
involves domains present on extracellular loop 1 as well as on extracellular loops 3 and 4 [15].  
Synthetic peptides corresponding to the new N-terminal sequence have been shown to 
activate the receptor, generating downstream signals in mammalian cells [15, 20].  While the 
tethered ligand sequences shown in Figure 3B are made up of six amino acids ending with 
Asp, a minimal peptidomimetic compound, PAR1-activating peptide (PAR1-AP), corresponds 
to the five amino acids, Ser-Phe-Leu-Leu-Arg, that immediately follow the cleavage site.  
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Figure 4: Thrombin binding to PAR1 exodomain. The globular protein thrombin binds to 
the exodomain of the PAR1through polar and hydrophobic interactions. The extremity of the 
N-terminal fits into thrombin’s active site where it is cleaved, yielding a new N-terminal 
(denoted as N in figure) which acts as a tethered ligand.  The tethered ligand (marked ligand in 
figure) can then activate cell signalling through an interaction with another area of the 
exodomain labelled ligand binding site-1 (LBS-1).The minimal peptidic sequence known to 
activate PAR1 corresponds to the five amino acid sequence Ser-Phe-Leu-Leu-Arg. (adapted 
from [15]) 
 
 
1.2.3 PAR1-mediated role of thrombin 
 
The thrombin receptor was the first PAR to be identified in its subclass, which is the 
reason for it having been named PAR1. It is a well-studied member of the PAR superfamily.  
Genetic and physical mapping of this receptor led to the recognition of additional protease-
activated receptor subtypes, including PAR2 [21], PAR3 [22], and PAR4 [23].  While PAR1, 
PAR3 and PAR4 are activated by thrombin, PAR2 is activated by the Tissue Factor/VIIa 
binary complex and by Factor Xa [6].  While mostly colocalized within 90kb of each other on 
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chromosome 5q13 [24], the human PAR4 gene is located on chromosome 19p12 [25]. PARs 
are often co-expressed and coactivation has been identified as a mechanism of action for some 
PARs in in-vitro testing [5]. 
For the purpose of this work, focus will be placed on PAR1, the first receptor identified 
in the PAR-superfamily.   
As thrombin results from the cleavage of prothrombin in the circulatory system, it is 
intuitive to deduce that blood components would be amongst the key targets of thrombin.  In 
particular, the PAR1 receptor plays a substantial role in platelet activation, particularly at low 
thrombin concentrations [8]. PAR1 activation in platelets is associated with platelet shape 
change, aggregation and granular secretion responsible for hemostasis which involves 
adenosine diphosphate (ADP), 5-hydroxytryptamine [26], platelet activating factor (PAF), and 
thromboxane [9]. Platelet shape change results in increased platelet adhesion to exposed 
tissues.  Platelet degranulation serves to amplify platelet aggregation. Activation of the platelet 
increases the cell-surface expression of glycoproteins IIb/IIIa – a fibrin cross-linking site 
essential for clot solidification.   
The inappropriate activation of platelets through the action of PAR1 can lead to serious 
medical conditions caused by the formation of thrombi, including myocardial infarct and 
stroke.  For this reason, PAR1 has the potential to be a useful pharmacological target. 
Zontivity™ (vorapaxar) which has been approved by the US Food and Drug Administration in 
May 2014 is the first pharmaceutical antagonist of PAR1.  
(www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm, 8/5/2014). 
In addition to its expression on platelets, PAR1 is also expressed on other cells. For 
example, macrophages [27], endothelial cells [7] and vascular smooth muscle cells [1] have.all 
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been shown to express PAR1 and are involved in a thrombin-mediated response to vascular 
injury [6].  
1.3 Protease-activated receptor 1 (PAR1) activation 
 
1.3.1 G-protein coupling to PAR1 and signalling cascade in mammalian cells 
 
The subtype of G-protein activated by a given receptor depends upon the 
transmembrane segments of receptors in concert with the cytoplasmic loops [28].  In the case 
of PAR1, coupling occurs in a promiscuous fashion with multiple G-protein families: Gα12/13 
[29],  Gαq [9] and Gαi/z [8], thus allowing for modulation of a number of intracellular 
signalling pathways, as described below and represented schematically in Figure 5. The first 
of these, Gα12/13, modulates shape change, the initial phase of platelet activation.  The 12/13 
subunit activates myosin light-chain phosphatases via Rho-guanine exchange factors (GEFs), 
activated Rho (small G-protein) and Rho-activated kinases. In some nucleated cells, this 
pathway mediates the function of cadherins, catenins and sterol-responsive element (SRE) 
required for permeability and migration in endothelial cells [9].   
 
 
 
 
 
 
 
 
Figure 5: PAR1 signalling cascade activation. The figure shows the downstream signalling 
cascades activated by the thrombin receptor in mammalian cells. (Adapted from [9]) 
0
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The Gβγ subunits can activate phosphoinositide 3-kinase (PI3-kinase), phospholipase 
Cβ (PLCβ), K+- ion channels, and GPCR-kinases and non-receptor tyrosine kinases [9]. 
Gαq coupling with PAR1 activates PLC and is primarily responsible for the formation 
of  inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), the by-products of hydrolysis 
of phosphatidylinositol 4,5-biphosphate (PIP2) [30]. Increased intracellular IP3 causes 
Ca
2+
mobilization from its intracellular stores, activation of plasma membrane Ca
2+
 channels , 
and activation of Ca
2+
 kinases including PKC, tyrosine kinases, mitogen-activated protein 
kinases (MAPKs) and RasGEFs [4]. 
DAG activates the protein kinase C (PKC) pathway. PKC’s activation mediates 
MAPKs, RasGEFs, Ca
2+
 activated kinases and receptor tyrosine kinases.  The substrates of 
these kinase reactions are also part of the Ras/MAPK cascade, thereby acting to enhance the 
initial response further and act as a feedback mechanism which terminates the activation of the 
signalling cascade [14]. In human platelets, a store-independent, non-capacitative Ca
2+
 entry 
(NCCE) pathway activated by DAG has been identified as a contributor to the thrombin-
induced increase in [Ca
2+
]i [31]. 
The PLC substrate pool is replenished via PI3-kinase activity.  Phosphorylation of 
pp125
FAK
, through the stimulation of Rho by the Gα subunit will precipitate pp125FAK binding 
to Src, which will also initiate downstream signalling and PI3K activation [14], thereby 
allowing for the DAG pathway to complement the actions of the IP3 pathway.  
Phospholipase D (PLD) activity can also be secondary to thrombin’s activation of 
PLCthrough phosphatidylinositol 4,5-bisphosphate and low molecular mass G-proteins (not 
shown in Figure 5).  PLD catalyzes the formation of phosphatidate from phosphatidylcholine 
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which is responsible for the production of arachidonic acid in platelets [14] which leads to 
platelet activation.  
The Gαi/z pathway is mainly responsible for PAR1’s inhibition of adenylyl cyclase 
(AC). AC catalyzes the conversion of ATP to cAMP and the inhibition of this conversion 
lowers cAMP levels and causes a corresponding decrease in protein kinase A (PKA) 
activation [9].  This cascade serves to modulate Raf activation via Ras activation.  Raf then 
relieves the inhibition of AC shutting down the cascade [14]. The βγ subunits, per se, may 
play a role in the transcriptional response and cell mobility through effectors such as PI3-
kinase, PLCβ, K+ channels, and G-protein coupled and non-receptor tyrosine kinases. 
However, particularly in platelets, the function of the βγ subunits is less well-established [30]. 
Finally, PAR1 has also been shown to signal through a 33 kDa serine-threonine protein 
kinase (PK33) in platelets.  PK33 is activated within seconds of either thrombin or PAR1-AP 
addition to platelets, and may be linked to potentiating the aggregation [32] which is induced 
by the PLC pathway. 
Therefore, activated PAR1 couples with several signalling cascades which are 
interrelated and interdependent, and coordination of the receptor’s activity relies heavily on 
switch kinases which provide relay stations for the integration of intracellular signals. 
  
1.3.2 Focus on Ca
2+
 mobilisation and store-operated Ca
2+
entry (SOCE) 
 
The present study assessed the signalling mechanism related to the mobilization of 
Ca
2+
in response to PAR1-AP in PAR1-Sf9 cells using pharmacological tools in an attempt to 
dissect out its various components.  
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In a GPCR signalling system, Gαq has been associated with the mobilisation of Ca
2+
. 
As previously mentioned, the PAR1-Gαq interaction leads to the activation of PLCβ. 
Activation of PLCβ, which can be inhibited by using D609, mediates the hydrolysis of 
phosphatidylinositol 4,5-biphosphate (PIP2) and subsequent formation of IP3 and DAG.  
Newly formed IP3 binds to IP3 receptor (IP3R)- Ca
2+
 channels, located in the membrane of the 
endoplasmic reticulum (ER), and activates an efflux of Ca
2+
 from the ER into the cytosolic 
space [33]. These Ca
2+ 
channels are importantly regulated by the presence of IP3 and Ca
2+
 
sensors located directly on the channel as well as by a number of protein kinases including 
PKA and PKC [33].  IP3R- Ca
2+
 channels can be inhibited either specifically through the use 
of TMB-8 [34] or concurrently with plasma membrane Ca
2+
 channels by using D-600 [35].     
The intracellular Ca
2+
 concentration ([Ca
2+
]i) is regulated by a plasma membrane Ca
2+
 
pump mediated transport which extrudes Ca
2+
 from the cytosolic space out of the cell  which 
is energized by adenosine triphosphate and by a thapsigargin-sensitive Ca
2+
-ATPase which 
transports cytosolic calcium into the ER and other organelles [36].  
Inhibition of the activity of PKA through the use of H-89 [37] would remove its 
contribution to modulating the IP3R- Ca
2+
 channel activation.  
The depletion of Ca
2+
 from the ER is detected by stromal interacting molecule-1 
(STIM-1) [38]. The activation of STIM-1 allows for its translocation to puncta, which refers to 
the interface between the ER and the plasma membrane.  Once translocated to puncta, STIM-1 
activates Orai-1 channels [39].  Orai-1 channels belong to a novel class of Ca
2+
 channels 
which may function as L-type Ca
2+
 channels and are lanthanum ion (La
3+
)-sensitive [38, 39]. 
 14 
 
The entry of Ca
2+
 from the extracellular space can be controlled either by using a Ca
2+
-
free medium or by inhibiting Ca
2+
 entry with Ca
2+
 channels inhibitors, such as La
3+
 [40], 
nifedipine [35] or D-600 [35].   
The second by-product of PIP2 hydrolysis is DAG.  DAG is a principal activator of 
PKC within cells. PKC, so named as it is a Ca
2+
-sensitive protein kinase, is a key modulator in 
the mobilization of Ca
2+
 throughout the cell.  PKC activity is associated with Ca
2+
 channel 
phosphorylation and inactivation, including the inactivation of Orai-1 channel phosphorylation 
[41]. It may also play a role in the phosphorylation of IP3R-activated Ca
2+
 channels [33, 42].   
The inhibition of PKC with bisindolylmaleimide [43] would prolong any increase in 
[Ca
2+
]i while the use of PDBu would potentiate PKC activity [44, 45], hastening the 
phosphorylation of PKC targets, including Ca
2+
 channel phosphorylation and inactivation. 
 
1.3.3 Inactivation of the receptor 
 PAR1 inactivation is a two-step process.  Initially, phosphorylation of serines and 
threonines on the cytoplasmic C-tail occurs, and is attributed to at least two protein kinases.  
The first is a PKC, and the second is a presumed G-protein receptor specific kinase, the beta-
adrenergic receptor kinase-2 (ARK2) [45].  Approximately 85% of the cell surface receptors 
are internalized in coated pits within one minute of activation; most of these are targeted to 
lysosomes [46]. Receptor internalization is specific to activated PAR1 [47] and the rate of 
reappearance of the cell’s response to thrombin suggests that de novo synthesis of the receptor 
is required.  However, recovery from the desensitized state, in response to PAR1-AP addition, 
can occur in mammalian cells within 30 to 60 minutes [47], suggesting some receptor 
recycling to the cell membrane.  
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 In endothelial cells and fibroblasts, a population of PAR1s located in intracellular 
pools has been identified [48].  These are transported to the cell surface following thrombin 
stimulation, allowing the cell to be reactivated rapidly. In platelets, it is unlikely that 
reappearance of receptors at the surface is required since platelets are activated only once [8]. 
 
1.3.4 Recent advances in understanding PARs 
Numerous biochemical advances have been made since the initial discovery of PAR1. 
To begin with, other proteases have recently been shown to cleave and activate 
PAR1, including factor Xa [49], plasmin [50], kallikreins [51, 52], activated protein C (APC) 
[53], matrix metalloproteinase-1(MMP1) [54], neutrophil elastase (NE) [55] and neutrophil 
proteinase-3 (PR3) [55].  The cleavage by these proteases reveals receptor-activating 
sequences that differ from each other [55] and are classified as ‘non-canonical’ tethered 
ligands.  Synthetic peptides derived from this ‘non-canonical’ cleavage of PAR1 (e.g. 
TLDPRSF-NH2 for a PR3 tethered ligand derived-activating peptide, or RNPNDKYEPF-
NH2 for a NE tethered ligand-derived activating peptide) can serve as ‘biased’ agonists of 
PAR1 to activate selective components of signalling, like MAPK, but not calcium signalling 
[55].  
At present, PAR signalling is known to activate several major signal pathways. First, 
and that which is the focus of this study, is the ‘classical pathway’ in which receptor activation 
causes signalling via G-proteins and downstream targets.  
It is, however, important to note that two additional pathways have been associated 
with PAR1 activity. The first of these includes a beta-arrestin signalling pathway involving 
ligand-regulated scaffolds [56]. Arrestin-bound GPCRs are uncoupled from their classical G-
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proteins to activate other signalling pathways [57]. Arrestin-dependent signals can be initiated 
by ‘biased’ agonists, creating the potential for drugs that can modulate specific GPCR 
function. 
It has recently been discovered that PARs are able to function both as monomeric 
receptors and as partners in a variety of complexes including homo- and heterodimers 
consisting of PAR-PAR, PAR-GPCR and PAR-non-GPCR [58]. This transactivation of a 
variety of receptors [58] and other signalling constituents (e.g. ion channels) is thought to 
occur through specific signalling components rather than by a physical interaction.  
The advances in the understanding of PARs point to the importance of studying the 
components of the PAR1 Ca
2+
 signalling cascade in that it could be critical to regulating one 
or more of the actions of the receptor.  
1.4  Spodoptera frugiperda (Sf9) cell line 
 
 Sf9 cells originate in the ovary of the fall armyworm Spodoptera frugiperda.  These 
cells are susceptible to infection by baculovirus type viruses. The baculovirus expression 
system is widely used for heterologous expression since it provides a eukaryotic environment 
which is ideal for the production of viable proteins, including mammalian proteins. The use of 
recombinant baculovirus has previously been used as a high-output expression system for 
mammalian proteins, including cell-surface receptors [59]. The baculovirus expression system 
functions in a simple viral fashion.  Infectious particles enter the host cells by receptor-
mediated endocytosis [60] and the viral DNA is uncoated in the nucleus.  Within 6 hours the 
entire viral DNA begins to replicate, at first releasing viral particles into the extracellular 
environment (also known as the budded virus).  The budded virus is responsible for the 
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infection in cell culture [60].  The later phase of infection is characterized by the appearance 
of occluded virus particles embedded in a polyhedrin protein.   
This polyhedrin protein is maximally expressed in the late phase of infection.  
However, this phase is not necessary for the viability of the virus in cell culture.  Insertion of 
heterologous DNA in place of the polyhedrin allow for replication to be controlled by the 
polyhedrin promoter, thus producing recombinant baculovirus in large quantity.  Infection of 
Sf9 cells according to this method allowed us to express a rat PAR1 which was believed to 
have proper folding, disulfide bonds, oligomerization, and most post-translational 
modifications. 
It is believed that the pharmacology of GPCR expressed using the Sf9/baculovirus 
system is similar to that in mammalian systems [40]. 
 It is well known that Sf9 cells possess an intrinsic seven transmembrane, GPCR for 
octopamine, a neurotransmitter. Functional studies have established that activation of this 
receptor and coupling to Gαs yields an increase in intracellular calcium through the release of 
Ca
2+
 from intracellular stores [61].  The Sf9 cell membrane is equipped with a potassium 
(K
+
)/hydrogen (H
+
) ion exchanger, a chloride (Cl
-
) channel, a muscarinic (M3)-G-protein 
coupled K
+
 channel and two distinct Ca
2+ 
 channels, one which is activated secondary to 
intracellular Ca
2+
 release from intracellular pools and is sensitive to lanthanum ions (La
3+
), 
and one which is muscarinic (M5) and is barium, gadolinium, and La
3+
-sensitive [40, 62]. 
The existence of several G-protein forms have been identified in Sf9 cells.  These 
include Gαi/z., Gα12/13 , Gαs and Gαq [26].  Both Gαi/z, Gα12/13 are found at lower levels while 
higher levels of Gαs and Gαq have been identified [63]. 
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It is believed that the insect cell Gαi/z-like proteins do not couple to mammalian GPCR 
whereas the remaining forms have been shown to couple to various mammalian receptors [40]. 
A number of additional signal transduction components have been identified in Sf9 
cells, including the presence of AC, PLC, and GPCR kinase [40].  
Therefore, expression of rPAR1 in Sf9 cells was meant to take advantage of a system 
made up of an isolated exogenous mammalian receptor coupled to the insect cell endogenous 
signalling cascades, especially that of intracellular calcium signalling, for the study of its 
activation by PAR1-AP, using Fura-2 microspectrofluoroscopy. 
1.5   Rationale, hypothesis and objectives 
The rationale of the current study was largely based on the material exposed in the 
previous sections. The important points that justify the present work are summarised below: 
1. The Sf9 insect cell system is an excellent way to express membrane proteins in 
large amount and at low cost;  
2. Sf9 cells have been shown to possess several components of the calcium 
signalling cascade, including Gαi/z., Gα12/13 , Gαs and Gαq, several of them being 
also found in mammalian cells; 
3. Calcium signalling is one of the several signalling mechanisms triggered by PAR1 
activation in mammalian cells (Figure 5). The exact mechanisms involved in the 
calcium response to PAR1 activation remain largely unknown , but are believed to 
represent new therapeutic targets for PAR-related pathologies. 
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It was therefore hypothesized that:  
1. the Sf9-baculovirus system represents a valid receptor expression tool for rPAR1, 
a mammalian GPCR, in isolation from other mammalian receptors;   
2. this exogenous protein functionally couples to the intrinsic Ca2+ signalling 
apparatus of Sf9 cells. 
  
 Consequently, the objectives of the study, and the associated approaches were: 
1. to determine whether rPAR1 is expressed and localized on the Sf9 cell surface, 
using immunofluorescence, confocal microscopy and fluorescence-activated 
cell sorting (FACS); 
2. to demonstrate that the receptor is coupled to Sf9 cells' calcium signalling, 
using single cell Fura-2 microspectrofluoroscopy; 
3. to identify components of Sf9 cells' calcium signalling machinery involved in 
mammalian rPAR1 activation, using pharmacological modulators that inhibit 
calcium transport in the plasma membrane channels (D-600, nifedipine, 
lanthanum), calcium sequestration in intracellular stores (thapsigargin) and 
calcium efflux from intracellular stores (TMB-8), and that modulate the 
functions of PLCβ (D-609, an inhibitor), PKA (H-89, an inhibitor) and PKC 
(PDBu, an activator; bisindolylmaleimide, an inhibitor). 
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2.1 Construction of the recombinant baculovirus rPAR1 and virus preparation 
 
Construction of the rat PAR1 recombinant baculovirus was prepared using the Blu-Bac 
(Invitrogen, Life Technologies, Burlington, ON) system for viral production. Messenger 
ribonucleic acid (mRNA) was purified from male Sprague Dawley rat lung tissue and 
transformed into single stranded complementary deoxyribonucleic acid (cDNA) by reverse 
transcriptase-polymerase chain reaction (RT-PCR) using oligo (dT) primers and Moloney 
murine leukemia virus reverse transcriptase.  Primers for nested PCR were designed according 
to the published sequence of the rPAR1 [64].   The primers: 5’thrrec-
TTGGATCCACAATGGGGCCCCGGCGCT-3’ (bp 71-89) and 5’thrrec-
TTCCAAGGTACTTCTTTTCCCATGGCC-3’ (bp 1315-1334), used for second round PCR 
incorporated BamHI and KpnI restriction sites at the 5’ and 3’ ends of the amplified product.  
Purified bacmid PCR II containing the rat PAR1 sequence obtained after transformation into 
E.coli MC1061 was sequenced and subcloned into the baculovirus transfer vector pJVETL at 
the BamHI/KpnI sites.  Cotransfection into Sf9 cells with linearized Autographa californica 
nuclear polyhedrosis virus (AcMNPV) using the lipofectin reagent yielded the recombinant 
virus.  
The recombinant virus was plaque purified through three rounds and blue plaques were 
selected in the presence of 5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside (X-Gal) and 
tested for the presence of occlusion virus.  At each stage of plaque purification, the presence of 
receptor cDNA was confirmed by dot-blot analysis of infected cell lysates hybridized to a 784bp 
cDNA probe.  Virus stocks were amplified, at 22
o
C, in Sf9 cells by infection of 40ml of cells at 
1 x 10
6
 cells/ml for 72 hours and collected.     
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2.2 Infection procedure 
 
 The Sf9 cells were grown in shaked capped Erlenmeyer flasks (Corning, Montreal, 
QC) at room temperature (22
o
C).  The growth medium, Grace’s Simplified Eagle’s Medium 
(Gibco BRL Life Technologies, Burlington, ON), was supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Hyclone, ThermoScientific, Menomonee Falls, WI, 
USA), and 0.1% pluronic acid F-68.   
The cells were grown between passages 6 and 65.  Immediately after each passage, 
densities ranged from 2 to 6x10
5
 cells/ml. They were then grown to densities between 1.5 and 
3 x10
6
 cells/ml.  Cell seeding for infection was performed by allowing cells to attach to the 
bottom of capped plastic culture flasks and further grown to cell counts in the range of 3 to 8 
x10
5
 cells/ml with virus addition performed at a multiplicity of infection (MOI) of 15. 
rPAR1-Sf9 cells were used for experiments between 25-48 hours following virus 
infection, and all assays were conducted at room temperature (22
o
C). 
2.3 Detection of expressed receptor in cell membranes  
2.3.1 Receptor–antibody cross-linking studies in rPAR1-Sf9 cells 
The binding assay was performed in essentially the same manner as the cross-linking 
assay, although the latter required the addition of a cross-linker.  Cells were prepared by growing 
to confluency in 6 well plates and rinsed three times with a refrigerated 0.1% bovine serum 
albumin (BSA)/ phosphate buffered solution (PBS), each rinsing occurring at 10 minute intervals 
with intermittent refrigeration.  In individual centrifuge tubes, 500l of solution containing the 
desired concentration of ligand diluted with 0.1% BSA/PBS was added, along with rPAR1 
expressing cells, and incubated on ice for three hours.  The tubes were labelled in the following 
manner: tube 1, 30nM hot; tube 2, 200nM hot; tube 3, 1000nM hot: tube 4, 30nM hot + 6M 
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cold; tube 5, 200nM hot + 40M cold; and tube 6, 1000nM hot + 200M cold (where: ‘hot’ 
refers to iodine labelled PAR1-AP while ‘cold’ refers to the non-iodinated PAR1-AP) The ligand 
was then aspirated and the cells washed once with ice cold PBS.  In the cross-linking experiment 
the cross-linker was added by the addition of 5mM bis (sulfosuccinimidyl) suberate (BS3) in 
PBS, followed by incubation and refrigeration for 5 minutes, addition of 100mM glycine, another 
5 minute incubation, and rinsing twice with 2ml PBS.  In all assays cell lysis was important, and 
was performed by the addition of a modified PBS solution made up of 1% triton X-100, 1mM 
ethylene-glycotetraacetic acid (EGTA) (Caledon Labs, Georgetown, Ontario, Canada), 1mM 
phenyl methyl sulfonyl floride, 10g/ml pepstatin (Sigma-Aldrich Chemicals, Milwaukee, WI, 
USA), 10g/ml leupeptin, 10g/ml antipain, 10g/ml benzamidine hydrochloride (HCl), 
10g/ml soybean trypsin inhibitor, 10g/ml aprotinin.   
After centrifugation  for 10 minutes at 13000 revolutions per minute (rpm) and  4
o
C, the 
supernatant containing the receptor was retrieved and placed in a gamma-counter prior to 
resolution on a 3-15% linear gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and autoradiographed.    
 
2.3.2 Western blot membrane preparation and endoglycosidase treatment of rPAR1 
Crude membranes were obtained according to the method previously described by 
Vouret-Craviari & al, 1995 [65] with slight modifications.  Sf9 cells in culture were infected 
with baculovirus rPAR1 at an MOI of 15, grown for 48 hours and collected at 500 x g. Cells 
were rinsed twice with 10mM tris (hydroxymethyl) aminomethane (Tris), pH 7.5, 1mM 
EGTA before harvesting in tris (hydroxymethyl) aminomethane buffer (TB) (5mM Tris, pH 
7.5) 0.5mM EDTA; 10g/ml each of the protease inhibitors leupeptin, aprotinin, pepstatin, 
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1mM Pefabloc
R 
 and phosphatase inhibitors 1mM orthovanadate and 50mM sodium fluoride 
(NaF) and incubated on ice for 5 minutes.  Subsequently, cells were disrupted by sonification 
and nuclei were removed by centrifugation (2000 rpm for 10 minutes at 4
o
C).  After 
centrifugation, crude membranes were resuspended in the same buffer and treated with 
endoglycosidase F according to the New England Biolabs’ (Ipswich, MA) protocol, except 
that all indicated procedures were carried out at room temperature.  Treated membranes were 
then applied onto a 7.5 % electrophoretic gel left running at 50 volts (V) for 2 hours.  The 
separation gel was prepared for immunoblot with a solution comprised of 60ml methanol, 3ml 
0.1% SDS, 909mg tris and 4.3mg glycine in a total volume of 300ml water (H2O). 
 Samples were separated on sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and blotted onto Hybond-C nitrocellulose membranes. The 
membranes were blocked with 0.5% I-Block (Applied Biosystems distributed by Life 
Technologies, Burlington, ON) and 0.3% Triton X-100 (Sigma-Aldrich Chemicals, 
Milwaukee, WI, USA) in PBS at 4°C and incubated for 1 hour (h) with specific antibodies 
(supplied by Dr. M.D. Hollenberg of the University of Calgary, Department of Medicine): 
anti-rPAR1 antibody (1:500 dilution), anti-mPAR2 antibody (1:500 dilution) or pre-immune 
serum (1:500 dilution). After a 30 minute wash, the membranes were incubated with anti-
rabbit horseradish peroxidase-linked secondary antibody for 1h and washed for another 30 
minutes. Immunoreactive protein signals were detected using the chemiluminescence (ECL) 
detection system from Amersham (distributed by GE Life Sciences, Baie d’Urfé, QC).  
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2.3.3 Immunocytochemistry, fluorescence-activated cell sorting (FACS) and confocal 
microscopy 
 
FACS allows for a quantitative analysis using cell sorting and laser-activated detection 
in a flow cytometer system whereby a suspension of cells is held in a funnel-like chamber.  
The system uses hydrodynamic focusing of the suspended cells (cell sorting), around a light 
source typically found in the narrower portion of the chamber.  The addition of a fluorescent 
probe (Oregon green-tagged polyclonal antibodies) to the cell suspension mixture increases 
the amount of fluorescence measured by the detection system located in close proximity to the 
light source, the scattered light, and any background fluorescent light. The fluorescence 
intensity is plotted as a function of cell number. 
Confocal microscopy is a high resolution imaging technique in which the excitation of 
a fluorophore (in our experiments, Oregon-green tagged polyclonal antibodies) is ensured 
through laser excitation of the sample, using a xenon lamp.  A confocal microscope uses the 
illumination of a single point of the sample and a pinhole in the emitted light pathway to 
measure the intensity of emitted light from a restricted field and in a narrow-thickness of 
sample slices. Only the light in a given spatial plane is detected at a given time within a 
corresponding confocal slice of about 0.2 to 0.3μm in width. Individual images of slices are 
obtained by scanning the sample line by line and three dimensional images are reconstructed 
using sequential vertical slices of the sample.  
Sf9 cells infected with rPAR1-cDNA were grown for 48h using the techniques 
described above. Cells in suspension FACS or plated on glass coverslips (for confocal 
microscopy) were washed twice with PBS (three times for confocal microscopy) and fixed 
with fresh 3% (v/v) formaldehyde in PBS for 20 minutes. Non-specific binding sites were 
blocked with PBS containing 1% I-Block (PBS-I-Block) for 1h at room temperature. The cells 
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were then incubated for 1h at room temperature with anti-rPAR1 receptor antibodies or pre-
immune serum diluted 1:50 in 0.5% PBS-I-Block. After three washings with 0.5% PBS-I-
Block, cells were incubated with Oregon-green-conjugated anti-rabbit immunoglobulin (Ig) G 
(1:2000 dilution, 1h at room temperature), used to reveal the primary antibodies.  The cells 
were detected using a Beckman-Coulter XL-MCL flow cytometry system (Mississauga, ON).  
 For confocal microscopy, rPAR1-Sf9 cells were left to adhere to 24mm circular glass 
coverslips for 30 minutes using the same method as that described for 
microspectrofluorescence.  Cell surface receptors were detected by Molecular Dynamics 
CLSM 2001 confocal microscope with inverted Nikon Diaphot fluorescent microscope 
(Amersham Biosciences, Sunnyvale, CA, USA)  using techniques previously described [66-
68].  
2.4 Functional assays 
 
2.4.1 Solutions 
 
 Measurements of calcium transients were conducted in one of three experimental media: 
2.8 Grace simplified medium (GSM), 6.8GSM, or 0GSM.  The media were composed of either 
2.8mM or 6.8mM CaCl2,  2 H2O or 2mM EGTA, 54.6mM KCl, 11.4mM MgCl2 X 6 H2O, 
11.3mM MgSO4 X 7 H2O, 11.2mM NaCl, 7.14mM PIPES- dipotassium salt, 2.86mM PIPES-
acid, 3.9mM D-glucose and adjusted to 340-380mOsm with sucrose, and a pH=6.4 with KOH.   
 All peptidomimetic compounds were prepared in distilled and deionized H2O to a 
stock concentration of 5mM and subsequently diluted to a final volume of 500l in the 
experimental solution.   
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2.4.2 Preparation and use of agonists and signal modulators 
 
Octopamine was used as a 5mM stock solution in H2O. Experiments were conducted 
using 20l of stock solution in 480l of 2.8 or 0GSM. 
Aliquots of thrombin were prepared using thrombin from human plasma (Sigma-Aldrich 
Chemicals, Milwaukee, WI, USA) diluted in H2O to produce a stock solution of 250U/ml. 
Experiments were also conducted using 20l of stock solution with 480l of 2.8 or 0GSM. 
 PAR1-AP was provided by the Peptide Synthesis Facility at BioChem Therapeutics 
(Laval, Quebec) as lyophylized powder. A 2mM stock solution was prepared using 20% EtOH / 
20% DMSO / 60% H2O. Experiments were conducted using 50l of stock solution in 450l of 
2.8 or 0GSM, to a final, supra-maximal dose of 100M. 
A solution of 5mM La
3+
 was prepared using 50ml H2O and 1.021g LaCl3 (Calbiochem, 
La Jolla, CA, USA) to produce a stock solution of 55mM. Experiments were conducted using 
50l LaCl3 solution in 500l of 2.8GSM.   
Stock solutions for 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8) 
(Alomone Labs, Jerusalem, Israel) as well as N-[2-[[3-(4-bromophenyl)-2-propenyl]amino] 
ethyl]-5-1 isoquinolinesulfonamide (H-89) (Sigma-Aldrich Chemicals, Milwaukee, WI, USA) 
and were prepared using H2O and tricyclodecan-9-yl xanthogenate (D-609) (Alomone Labs, 
Jerusalem, Israel),phorbol 12,13 dibutyrate (PDBu) (Sigma-Aldrich Chemicals, Milwaukee, 
WI, USA) and bisindolylmaleimide (Sigma-Aldrich Chemicals, Milwaukee, WI, USA)  were 
prepared using DMSO (Sigma-Aldrich Chemicals, Milwaukee, WI, USA) in a manner similar 
to La
3+
.   
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Nifedipine (Calbiochem, La Jolla, CA, USA) and methoxyverapamil (D-600) 
(Calbiochem, La Jolla, CA, USA) were diluted in DMSO to obtain stock solutions of 0.5mM 
and 5mM, respectively. Serial dilution of 20l of stock solution in 230l of GSM was 
performed and subsequently added to the experimental chamber which contained a starting 
volume of 250l, for a total final volume of 500l.  
A stock solution of 50M thapsigargin (Alomone Labs, Jerusalem, Israel), was also 
prepared using DMSO, and cells were bathed with 50M thapsigargin in 500l 0GSM for 5 
minutes prior to the addition of 100M PAR1-AP. 
  
2.4.3 Microspectrofluorescence 
 
Functional coupling of rPAR1 in the rPAR1-Sf9 cells was studied using a Photon 
Technology International’s DeltaRam/microscope (PTI) photometer system. A xenon lamp was 
used as a light source, and emitting light at alternating wavelengths of 340 and 380 nanometres 
(nm), directed via a 40x epifluorescence objective, at the Sf9 cells plated on coverslips and 
loaded with Fura-2 (Molecular Probes, Eugene, Oregon).  The fluorescent probe Fura-2 
fluoresces in response to this excitation, with the amount of light being a function of the [Ca
2+
]i .  
The emitted fluorescence is captured through a 505nm emission filter by a photon-counting 
detector connected to a computer. 
Fura-2 cell loading was realized by using the Fura-2 AM fluorophore (Molecular Probes, 
Eugene, Oregon), a cell permeant compound. Fura-2 AM is hydrolyzed by intracellular esterases 
to form Fura-2 which remains trapped in the cells.  Upon binding to Ca
2+
, the excitation spectra 
of Fura-2 undergoes a shift in fluorescence to lower wavelength.  This spectral property of Fura-
2 was used for high-sensitivity determination of intracellular Ca
2+
 concentration.  Using the ratio 
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of Fura-2 intensities from cells excited at 340nm and 380nm provides higher dynamic range and 
makes the measurements largely independent of volume change artefacts. Therefore, 
fluorescence ratio versus time was used to determine the cellular response in the functional 
assays. The procedure to obtain intracellular calcium concentration from fluorescence 
intensities and ratios is described in Appendix 1. 
Between 25 and 48 hours post infection, 500 μl of cells were plated onto 24mm circular 
glass slides and left to adhere for 30 minutes.  Once attached, the cells were rinsed twice with 
6.8GSM.  Cells were then loaded with the Ca
2+
-insensitive Fura-2 AM and washed three times 
following 30 minutes of incubation at room temperature.  
Fura-2 measurements were performed on single cells that were optically isolated under 
microscopic observation by means of an adjustable rectangular aperture located in the emission 
path of the microspectrofluorometer.    
Results are presented as normalized ratio, with baseline [Ca
2+
]i levels adjusted to ratio 
level 1, for simplicity sake.Fluorescence ratios were normalized according to the following 
transformation: 
(F340/F380)/(F340/F380)t=0 
 Glass coverslips were then mounted in a custom-made experimental chamber containing 
a final volume of 1ml of 2.8GSM or 0GSM. 
 All figures are representative of at least 3 identical experiments.  
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3.1 Sf9-baculovirus expression system of rPAR1 receptor 
3.1.1 Successful expression of rPAR1 
 In order to establish the successful expression of rPAR1 using the Sf9-baculovirus 
expression system, assays were initially conducted as described in the Materials and Methods 
(section 2.3). 
To evaluate protein expression of rPAR1 in rPAR1-cDNA-containing baculovirus 
infected Sf9 cells (rPAR1-Sf9), western blots were performed as shown in Figure 6.  Western 
blot analysis uses gel electrophoresis to separate proteins by molecular weight.  Smaller 
proteins migrate more quickly through the polyacrylamide gel while larger proteins migrate 
more slowly. The anti-PAR1 antibody recognized a band in membranes obtained from Sf9 
insect cells infected with ratPAR1-cDNA containing baculovirus, as shown in Figure 6, lane 5.  
The band seen with the anti-rPAR1 antibody was specific to rPAR1 since it was absent in the 
non-infected Sf9 cells (lane 4) and the pre-immune serum (lanes 1-3). 
Given that potential sites for N-linked glycosylations are present on rPAR1, freshly 
prepared membranes from rPAR1-Sf9 or Sf9 wild type were treated with N-glycosidase F to 
remove all asparagine-linked carbohydrates from the protein.  The deglycosylation resulted in 
a decrease in the apparent molecular mass for rPAR1 to approximately 40kDa.  This is 
consistent with the literature which indicates that while the mature receptor has a molecular 
mass ranging from 68 to 80 kDa, N-linked glycosylations represent 32-40 kDa [65].  
 Anti-rPAR1 antibodies (supplied by Dr. M.D. Hollenberg of the University of 
Calgary, Department of Medicine) were used to perform western blot analysis.   
Binding and cross-linking studies were attempted using radioiodinated peptides in order 
to confirm the binding specificity of the PAR1-AP. A total of three attempts failed to be 
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successful, and it was later discovered that the antibody iodination process had been unsuccessful 
and further cross-linking studies were not attempted. However, various other assays were used to 
determine successful receptor expression.  
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Figure 6: Western blot analysis of rPAR1 infected Sf9 cells.  MW: molecular weight 
markers (kDa). Lanes 1-3: pre-immune serum in non-infected Sf9 (lane 1), rPAR1 infected 
Sf9 (lane 2), and mPAR2 infected Sf9 (lane 3). Lanes 4 and 5: anti-rPAR1 antibody: non-
infected Sf9 cells (lane 4), rPAR1 infected Sf9 cells (lane 5). 
 
 
3.1.2 Localization of the rPAR1 receptor expressed in Sf9 cells 
 
3.1.2.1 Receptor localization using FACS 
 
Assays were performed using immunocytochemistry techniques to determine whether 
translocation of the protein to the cell surface had been successful.  The first of these were 
conducted using FACS.  Results are shown in Figure 7. The baseline level of scattering and 
Band reflecting 
deglycosylated 
rPAR1 
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emission of light by the rPAR1 infected Sf9 cells is shown in green (control). This control 
contains neither preimmune serum nor tagged-antibody.  The blue line depicts the 
fluorescence measured in rPAR1-Sf9 cells which have been treated with preimmune serum 
(serum-control). Results are virtually superimposed, with fluorescence being only slightly 
affected by the incubation with pre-immune serum, which may mainly be due to 
autofluorescence of serum proteins.  As shown by the red curve, the rPAR1-Sf9 cells treated 
with anti-rPAR1 tagged antibodies emitted a higher level of intensity due to the cell-surface 
linked fluorescent probes, demonstrating the successful expression of the rPAR1 on the cell 
plasma membranes of infected Sf9 cells (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: FACS analysis of rPAR1 expression Green curve: non-infected Sf9 cells with no 
preimmune serum and without tagged antibodies. Blue curve: rPAR1-infected Sf9 cells with 
preimmune serum. Red curve: rPAR1-infected Sf9 cells with anti-rPAR1-antibody. The shift 
to the right of the curve indicates linking of fluorescent-tagged secondary antibodies. Samples 
were made of 100 cells each. 
 
 
3.1.2.2 Receptor localization using confocal microscopy 
 
 Confocal microscopy was also used to establish successful rPAR1 expression and to 
find out where the receptor was localized. As shown in Figure 8, confocal images using 
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Oregon-green tagged polyclonal antibodies demonstrated that the rPAR1 receptors were 
expressed and translocated mainly onto the surface of rPAR1-Sf9 cells (Figure 8 images 4 and 
6). The results showed also that some receptors were located in the cytoplasmic space (Figure 
8 images 2, 3 and 5), representing either a mature or a functional receptor pool, or both, or 
were simply reflective of receptor cycling.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Different views of confocal micrographs of a single Sf9 cell expressing rPAR1. 
1: top view of the cell. 2, 3 and 5: view of individual cell slices showing fluorescent receptors 
concentrated along the periphery of the cell as well as areas of increased receptor density in 
the cytoplasmic space (in green) . 4: vertical view of the cell, clearly demonstrating the 
location of the rPAR1 along the cell surface. 6: bottom surface of the cell (closest to the glass 
coverslip) showing dense localization of the fluorescent receptors on the cell surface. 
 
 
3.2 Changes in [Ca
2+
]i concentration using octopamine 
 
 Control experiments were conducted to establish that [Ca
2+
]i changes could be 
observed in wild-type and infected Sf9 cells in response  to the endogenous agonist 
octopamine [69].  Wild-type Sf9 cells are known to respond to octopamine as the activation of 
1 2 3
4 5 6
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the cell-surface receptors yields intracellular Ca
2+
 signals detected using Fura-2 [70].  
Therefore, the octopamine test was used to ensure the physiological competence of wild-type 
and baculovirus-infected Sf9 cells used in the present work.  
Figure 9 (green trace) shows the [Ca
2+
]i of a single wild-type Sf9 cell following the 
addition of 100 M octopamine in the absence of external calcium (0GSM). As expected, 100 
M octopamine induced a surge in [Ca2+]i.  In the calcium-containing experimental medium 
(2.8GSM), the initial [Ca
2+
]i surge was followed by a second phase consisting of a longer-
lasting plateau (Figure 9, violet trace). Initial studies suggested that the octopamine response 
may point to an influx of Ca
2+ 
[70], and subsequent studies supported the findings that this 
second phase of the octopamine response was likely a calcium influx through Ca
2+
 channels of 
the cell membrane [69]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Effect of octopamine on cytosolic calcium in wild-type Sf9 cells. 
Sf9 cells were stimulated by the addition of 100 M octopamine (as indicated by the arrow) in 
the presence of extracellular Ca
2+
 (violet trace) or in the absence of extracellular Ca
2+
 (green 
trace).  Data reported is representative of three identical experiments. 
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The octopamine test was used in infected cells to determine whether the pathogen 
would ultimately affect the Sf9’s functionality and to determine the optimal time window to be 
used for the functional assays of rPAR1expressed in the cells. Although biphasic responses 
were generally recorded, a significantly reduced competency of the cells was observed after 
prolonged viral exposure (Figure 10). These experiments demonstrated also that the 
octopamine receptors remained functional in rPAR1 expressing cells.  
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Figure 10: Effect of infection time on intracellular Ca
2+
 concentration change in response 
to octopamine in baculovirus-Sf9 cells.  The experiment was conducted in the presence of 
extracellular Ca
2+
. Each trace represents the response of a single Sf9 cell to the addition of 100 
M octopamine at t=50 seconds. Red trace: calcium transient in cell 26.5 hours post infection. 
Blue trace: calcium transient in cell 49 hours post infection. Data shown is representative of 
three identical experiments. 
 
The Sf9-baculovirus system was shown to express significant levels of exogenous viral 
proteins as early as 22 hours following infection [60] and could be detected as far as 60 hours 
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post-infection (data not shown) . Experiments were performed between 25 and 48 hours post 
infection to ensure the cells were functional.  
Control experiments were performed with the various agonists, inhibitors and 
modulators used throughout the course of this study on Ca
2+
 signalling in rPAR1-expressing 
Sf9 cells. Table 1 summarizes the qualitative changes observed when the various agents were 
added to wild-type Sf9 cells.  The results obtained suggest that these compounds had no effect 
on wild-type Sf9 cells. 
Agonist/inhibitor/modulator/vehicle Qualitative change vs baseline in ratio 
representing [Ca
2+
]i 
Ca
2+
-rich medium Ca
2+
-free medium 
octopamine (insect neurohormone agonist) +++ (biphasic) +++ (peak) 
thrombin (PAR1 agonist) n.e. n.e. 
PAR1-AP (PAR1 agonist) n.e. n.e. 
La
3+
 (Ca
2+ 
channel & pump inhibitor) n.e. n.e. 
nifedipine (L-type Ca
2+
 channel inhibitor) n.e. n.e. 
D-600 (voltage dependent Ca 
2+
inhibitor) n.e. n.e. 
thapsigargin (Ca
2+
-ATPase inhibitor) + + 
TMB-8 (IP3R- Ca
2+
 channel inhibitor) n.e. n.e. 
D-609 (PLCβ modulator) n.e. n.e. 
bisindolylmaleimide (PKC modulator) n.e. n.e. 
PDBu (PKC modulator) n.e. n.e. 
H-89 (PKA modulator) n.e. n.e. 
vehicles n.e. n.e. 
 
 
Table 1: Summary of qualitative changes in Fura-2 fluorescence ratio reflecting [Ca
2+
]i 
in control experiments. Agonists, inhibitors, solvents or modulators were diluted in vehicle 
and added to wild-type Sf9 cells (n=3) in Ca
2+
-rich or Ca
2+
-free medium. Large biphasic 
responses in ratio reflecting calcium are indicated (+++). Slight increase (+) in [Ca
2+
]i is 
indicated. Slight increase with thapsigargin may due to a slight increase in cytosolic [Ca
2+
] 
when the Ca
2+
-ATPase is inhibited. Other agents, modulators and vehicles had no effect (n.e.) 
on the [Ca
2+
]i of cells.  
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3.3 Functional coupling of rPAR1 in Sf9 cells 
 Once it was established that rPAR1 could be successfully expressed in Sf9 cells, the 
next step was to investigate whether this receptor could couple functionally to the Sf9 cell’s 
signalling apparatus and, if so, to characterize the response to its agonist. 
 
3.3.1 Effect of thrombin 
 
In order to determine whether the rPAR-Sf9 possessed an exodomain highly similar to 
mammalian cells, that will bind and be activated by thrombin’s serine protease activity, 
thrombin was used to stimulate the rPAR1-Sf9. Typical rPAR1-Sf9 responses are shown in 
Figure 11, which demonstrates functional coupling of the rPAR1 to Ca
2+
 signalling in the Sf9 
cell, in the presence or absence of extracellular Ca
2+
. The arrow indicates the time of addition 
of 10 U/ml of thrombin to a final volume of 1ml in the experimental chamber.  
In the presence of extracellular Ca
2+
 (2.8GSM), thrombin produced a biphasic increase 
in intracellular calcium concentration, consisting of an initial surge followed by a slow return 
to baseline in a plateau-like fashion.  In calcium-free medium (0GSM), only the first phase of 
the response was observed, consisting of the initial surge followed by a rapid return to 
baseline.  The amplitude differences noted in the ratio is due to variability in individual single 
cell responses.  
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Figure 11: Effect of thrombin on [Ca
2+
]i in Sf9 insect cells expressing rPAR1. The 
functional coupling of rPAR1 to the Ca
2+
 signalling apparatus of the Sf9 cell system is 
apparent by the calcium surge which follows the addition of 10U/ml of thrombin (arrow) to 
the Sf9-rPAR1 cell. The initial surge in [Ca
2+
]i is comparable in both calcium-free (turquoise 
trace) and calcium-containing (pink trace) media, but when Ca
2+
 is present in the extracellular 
space, a plateau follows the initial phase.   
 
3.3.2 Effect of PAR1-AP 
 
In mammalian cells, PAR1-AP, a small, 5 amino acid peptide (Ser-Phe-Leu-Leu-Arg), 
identical to the minimal region of the truncated N-terminus of the thrombin-cleaved PAR1, 
acts as an agonist to the receptor [20]. The activity of PAR1-AP was tested on PAR1 Sf9 cells 
to confirm whether the ligand binding sites present on the receptor exodomain were held in a 
conformation consistent with that in mammalian cells.  Figure 12 shows that the PAR1-AP 
triggered responses which were similar to those obtained with thrombin: an initial [Ca
2+
]i 
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surge was followed by a plateau phase in 2.8GSM, whereas the response to PAR1-AP 
comprised only the initial [Ca
2+
]i surge in 0GSM. 
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Figure 12: Effect of synthetic peptide PAR1-AP on [Ca
2+
]i in rPAR1-Sf9 cells. The 
addition of 50 M PAR1-AP (arrow) yielded a response which was qualitatively similar to 
those produced by the addition of thrombin.  The maroon trace demonstrates the typical 
biphasic response obtained in calcium containing medium, whereas the blue line demonstrates 
the response obtained in a calcium-free medium.  
 
Overall, the intracellular Ca
2+ 
concentration changes produced following either 
thrombin or PAR1-AP addition were comparable in their kinetics. In 2.8GSM, the agonists 
produced an initial large peak in the intracellular Ca
2+
 level, within 10 seconds of the addition 
of agonist. The intracellular Ca
2+
 signal then decreased somewhat, but remained sustained in a 
plateau phase and remained high for up to 6 minutes. In the presence of external Ca
2+
 the 
surge was generally greater.  In the absence of extracellular Ca
2+ 
(0GSM), the plateau phase 
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was not observed and instead, intracellular calcium concentration levels returned rapidly to the 
initial level.    
 
3.4 Modulation of the rPAR1-Sf9 cell signal 
 
 The experiments described above demonstrated that the rPAR1-Sf9 expression system 
yielded a receptor protein functionally similar to that found in mammalian cells, in terms of 
responsiveness to thrombin and PAR1-AP. Therefore, the receptor could be studied, isolated 
from other mammalian receptors, using the Sf9-baculovirus expression system.   
While PAR1-AP has been shown to activate PAR1 at concentrations of 0.5-6 μM [4], 
dose-response curves were not attempted, instead, to achieve full activation of the Ca
2+
 
signalling process in rPAR1-Sf9 cells, supra-maximal doses of PAR1-AP, i.e. 50-100μM, 
were used in all experiments described in the following sections.   
 
3.4.1 Effect of calcium-channel inhibitors  
 
By examining the results we obtained by rPAR1 stimulation by thrombin or PAR1-AP 
in calcium-deficient and calcium-rich conditions, we believed that the Ca2+ response was a 
biphasic process characterized by a release of Ca2+ from internal stores coupled to an influx 
dependent on the presence of Ca
2+
 outside the cells.  
 In order to study the mechanisms involved in Ca
2+ 
influx into the cells, various plasma 
membrane calcium inhibitors were used, either before or after the stimulation of the cells by 
PAR1-AP in the presence of extracellular Ca
2+
. The effects of La
3+ 
ions, nifedipine and D-600 
are described in the following sections. 
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3.4.1.1 Effect of lanthanum 
 La
3+
 is a widely used inorganic calcium influx inhibitor. Results shown in Figure 13 
show that pre-incubation of rPAR1-Sf9 cells with 5mM La
3+ 
caused a rapid return to the 
baseline [Ca
2+
]i  when PAR1-AP was added.  This pre-incubation with 5mM La
3+ 
yielded a 
PAR1-AP response similar to what was obtained in a calcium-free solution. 
When rPAR1-Sf9 cells were stimulated with PAR1-AP, La
3+ 
could be added within 
seconds (Figure 15), and will also truncate the second phase of the response and cause a more 
rapid return to baseline.  
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Figure 13: Effect of La
3+
 pre-incubation on the [Ca
2+]
i response to PAR1-AP.  
The figure demonstrates the effect of the addition of 5mM La
3+ 
at 45 seconds (first arrow) 
followed by 50 M PAR1-AP at 145 seconds. Addition of 50µM PAR1-AP is indicated by the 
second arrow.  La
3+
 in a Ca
2+
-rich medium prevents the entry of Ca
2+
 from the extracellular 
space and yields a response that is similar to what is typically seen in the absence of 
extracellular Ca
2+
. 
 
 
While La
3+
 is widely used as a general, or non-specific, Ca
2+
 channel and influx inhibitor, Sf9 
cells are known to specifically possess voltage-dependent and L-type Ca
2+
 channels [40].   
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Figure 14: Effect of La
3+
applied during the [Ca
2+
]i surge triggered by PAR-AP. Addition 
of 100µM PAR1-AP (first arrow) followed by 5mM La
3+
 (second arrow). The inhibition of 
Ca
2+
 channels truncated the typical response to PAR1-AP. 
 
The role of these Ca
2+
 channels in the Ca
2+
 response following heterologous receptor 
expression has not been definitively demonstrated [70]. The possible involvement of these 
channels in the plateau phase was therefore further assessed using nifedipine and D-600. 
 
 
3.4.1.2 Effect of nifedipine  
 
Nifedipine is a dihydropyridine known to specifically inhibit L-type calcium channels 
[71]. Figure 15 demonstrates that nifedipine interfered with the second phase of the Ca
2+
 
response demonstrating a the contribution of Ca
2+
 channels to this component of the response.  
 Addition of PAR1-AP followed closely by nifedipine yielded a PAR1-AP response 
similar to what was seen in calcium free experiments (Figure 15), suggesting that the second 
phase of the response was mediated by the activation of L-type calcium channels. 
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Figure 15: Effect of nifedipine on the Ca
2+
 flux produced by PAR1-AP activation in 
rPAR1-Sf9 cells. Orange trace represents 100µM PAR1-AP at 50 seconds followed by 10µM 
nifedipine at 75 seconds in the presence of extracellular Ca
2+
. 
 
Addition of PAR1-AP followed closely by nifedipine yielded a PAR1-AP response 
similar to what was seen in calcium free experiments (Figure 15). This result suggests that the 
second phase of the Ca
2+
 response was mediated by the activation of L-type calcium channels. 
This is, however, no effect of nifedipine on the action of IP3R Ca
2+
 channels as its action is 
restricted to the Ca
2+
 channels present in the plasma membrane. 
 
3.4.1.3 Effect of D-600 
 
D-600 is a lipophilic, organic voltage-dependent calcium-channel blocker. This agent 
can exercise its action intracellularly as well as extracellularly [71].  Use of D-600 after cell 
stimulation by PAR1-AP induced oscillations during the plateau phase of the [Ca
2+
]i response 
(Figure 16, green trace). On the other hand, pre-incubation with D-600 caused a full inhibition 
of the PAR1-AP response (Figure 16, blue trace). 
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Figure 16: Effect of D-600 on the [Ca
2+
]i response to PAR1-AP .  Attenuation of the PAR1-
AP response occurs following incubation of cells with 100µM D-600 (blue trace), the first 
arrow indicates addition of D-600 while the second arrow indicates of the addition of PAR1-
AP. The green trace shows the addition of 100µM PAR1-AP (first green arrow) quickly 
followed with D-600 (second green arrow) in a Ca
2+
 containing environment. 
 
The results obtained (Figure 16) suggest that in rPAR1-Sf9, incubation of cells with D-
600 allows it to act as an intracellular Ca
2+
 channel blocker similar to TMB-8.  Oscillations 
caused by the addition of D-600 immediately following PAR1-AP suggests that D-600 
interferes with the return to baseline [Ca
2+
]i.   
   
3.4.2 Effect of other calcium transport modulators 
 
 Once it was established that the second phase of the intracellular Ca
2+
 surge observed 
in response to thrombin and PAR1-AP stimulation was likely due to the influx of extracellular 
Ca
2+
 through L-type Ca
2+
-channels of the plasma membrane of the cells, experiments were 
conducted to determine what was responsible for the initial phase of the surge observed in 
calcium-free solution or in the presence of calcium transport blockers. 
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3.4.2.1 Effect of thapsigargin 
 
  
 
 
 
 
 
 
 
 
 
Figure 17: Effect of thapsigargin on the [Ca
2+
]i response to PAR1-AP activation in 
rPAR1-Sf9 cells. Addition of 100nM thapsigargin (first arrow) is followed by a slow increase 
in [Ca
2+
]i as Ca
2+ 
passively exits the ER, travelling down the concentration gradient.  The 
addition of 100M PAR1-AP (second arrow) does not produce any increase in [Ca2+]i.   
 
 Thapsigargin is a calcium-ATPase inhibitor which inhibits calcium resequestration in 
intracellular Ca
2+
 storage sites.  Thapsigargin is also known to cause an influx of Ca
2+
 from 
extracellular space in the absence of any phosphoinositide hydrolysis, a phenomenon 
prevented here by the use of calcium-free medium. As shown in Figure 17, the 5-minute 
incubation of rPAR1-Sf9 cells with 100nM thapsigargin in calcium-free medium caused a 
slight surge in [Ca
2+
]i immediately following the addition of thapsigargin to the experimental 
chamber, as has been reported previously [72].  Pre-treatment with thapsigargin completely 
abolished the [Ca
2+
]i surge normally induced by the PAR1-AP peptide, as described above.  
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3.4.2.2 Effect of TMB-8 
 
TMB-8 is an IP3R-Ca
2+
 channel antagonist which prevents the release of Ca
2+
from 
internal stores, the ER in particular. Pretreatment with 100 M TMB-8 inhibited the PAR1-AP 
effect in 50% of the rPAR1 expressing cells tested in 2.8GSM (Figure 18 and Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
Figure 18: TMB-8 inhibition of Ca
2+
 release from the ER. In Ca
2+
-rich media, 100µM 
TMB-8 inhibited the Ca
2+
 transient normally produced by 50 µM PAR1-AP.  No change in 
ratio reflecting Ca
2+
 was anticipated, but was only seen in 50% of the cells tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Ineffective inhibition by TMB-8. 100µM TMB-8 did not consistently inhibit the 
Ca
2+
 transient produced by 50µM PAR1-AP in Ca
2+
-containing media. 
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It was noted that in experiments in which the PAR1-AP response was abolished in 
2.8GSM, a minimum 5-minute pre-incubation period with TMB-8 was required to inhibit the 
Ca
2+
 transient entirely. 
In the absence of extracellular Ca
2+
, 100% of the cells tested showed total suppression 
of the calcium transient produced by PAR1-AP, therefore, similar to Figure 18A, no change to 
the ratio reflecting [Ca
2+
]i, even when incubated with TMB-8 for short periods of time 
(between 250 and 300 seconds).  The results suggest that the Ca
2+
 surge was indeed made of 
Ca
2+
 release from internal stores, particularly the ER.  
It is difficult, however, to conclude whether TMB-8 is an effective signal modulator in 
Sf9 cells as responses lacked consistency but previous studies have successfully used TMB-8 
as a IP3R-Ca
2+
 channel inhibitor. 
 
3.4.3 Signal cascade modulation 
 
 The results described in the preceding sections demonstrated that the Ca
2+
 surge 
triggered by PAR1 activation was made of two components: the influx of extracellular Ca
2+
 
and the release of Ca
2+
 from internal stores.  The following sections are devoted to further 
studies aimed at exploring the components of the signalling cascade involved in the PAR1-AP 
induced response. 
 
3.4.3.1 Effect of D-609 
 
D-609 is a PLCβ inhibitor [73].  In order to determine the role of PLCβ in the [Ca2+]i 
surge in response to PAR1-AP stimulation, D-609 was used. Figure 20 shows that regardless 
of the presence or absence of extracellular calcium, the response elicited by PAR1-AP was not 
affected by the addition of 100M D-609 five minutes prior to the addition of 50M PAR1-
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AP, suggesting that PLCβ does not appear to be involved in the pathway linking PAR1 to the 
release of Ca
2+
 from intracellular stores.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Effect of D-609 on the [Ca
2+
]i response to PAR1-AP. In Ca
2+
-free medium 
(purple trace), rPAR1-Sf9 cells were incubated with 100 M D-609 for 5 minutes followed by 
the addition of 50 M PAR1-AP (purple arrow).  In a Ca2+-rich environment (blue trace) 
shows a cell previously incubated for 5 minutes and the addition of 50 M PAR1-AP (blue 
arrow).  
 
3.4.3.2 Effect of protein kinase modulators 
 
3.4.3.2a Effect of bisindolylmaleimide 
 As mentioned in section 1.3, PAR1 coupling to Gαq activates PLCβ with the 
subsequent formation of IP3 and DAG.  The DAG pathway will lead to downstream activation 
of PKC which ultimately replenishes the Gαq substrate pool.  Bisindolylmaleimide has been 
shown to interfere in this signalling cascade through the inhibition of PKC [43].  This 
inhibition depletes the PLCβ’s substrate pool.   
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The effect of bisindolylmaleimide on the [Ca
2+
]i signal varied with the experimental 
conditions. As shown in Figure 21, in a Ca
2+
-free medium, addition of 200nM of the inhibitor 
prior to that of PAR1-AP significantly blunted the Ca
2+
i signal. On the other hand, this 
compound used in the presence of extracellular Ca
2+
 did not affect the magnitude of the 
response to PAR1-AP, but it induced oscillations following the initial surge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Effect of bisindolylmaleimide on the [Ca
2+
]i response induced by PAR1-AP. 
Incubation of rPAR1-Sf9 cells with 200nM bisindolylmaleimide followed by 100µM PAR1-
AP in Ca
2+
-free environment (purple trace).  In a Ca
2+
-rich medium, 200nM 
bisindolylmaleimide followed by 100µM PAR1-AP shows a large Ca
2+
 flux followed by rapid 
decrease in intracellular Ca
2+
 and [Ca
2+
]i oscillations (blue trace).  
 
3.4.3.2b Effect of PDBu 
 PDBu is a protein kinase C activator [44]. Figure 22 (blue trace) shows that the second 
phase of the PAR1-AP-induced Ca
2+
 response in 2.8GSM was significantly reduced in the 
presence of PDBu. However, in the absence of extracellular Ca
2+
, rPAR1-Sf9 cells incubated 
in PDBu did not respond to PAR1-AP stimulation (Figure 22, brown trace). 
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Figure 22: Effect of PDBu on the Ca
2+ 
surge produced by PAR1-AP. Incubation with 
200nM PDBu for 5 minutes (at 50 seconds, first arrow) followed by the addition of 50µM 
PAR1-AP (at 350 seconds, second arrow).  The blue trace shows an attenuated response to 
PAR1-AP with virtually no second or plateau phase in calcium-rich medium.  The brown trace 
shows that incubation with PDBu suppressed the Ca
2+
 surge in Ca
2+
-free environment.  
 
Altogether, the results from the experiments conducted with PKC modulators 
demonstrate that this kinase plays an active role in the Ca
2+
 signalling pathway activated by 
rPAR1.   
 
3.4.3.2c Effect of H-89 
 H-89 is a PKA inhibitor that is believed to competitively bind to the ATP 
binding site on the catalytic subunit of PKA, thereby interfering with the Gi/Gs-AC pathway, 
by blocking the phosphorylation of PKA [74].  Figure 23 shows that in cells pre-incubated 
with H-89, an increase in plateau duration was observed in response to PAR1-AP in a Ca
2+
-
rich environment.  On the other hand, incubation of the cells with this compound resulted in 
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the complete inhibition of the PAR1-AP response in Ca
2+
-free environment.  This data clearly 
demonstrates the involvement of PKA in the [Ca
2+
]i  signalling cascade. Whereas H-89 had a 
substantial effect on the Ca
2+
 signal induced by PAR1-AP, recent uncertainty about the 
activity of H-89 [37] makes it impossible to decipher what mechanism is affected by this 
agent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Effect of H-89 on the [Ca
2+
]I response to PAR1-AP.  Addition of 100μM PAR1-
AP in rPAR1-Sf9 cells preincubated with 500nM H-89 in a Ca
2+
-rich medium (blue trace) and 
Ca
2+
-free medium (pink trace). Arrow indicates the addition of 100 μM PAR1-AP in both 
cases. 
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Thrombin’s proteolytic action is a critical step in the coagulation cascade.  Whereas 
historically, thrombin’s role in cleaving fibrinogen was considered its exclusive action, the 
receptor-mediated activity of thrombin allows it to act on a variety of cellular targets. A 
number of thrombin receptors have been identified, including PAR1 [4]. 
On the other hand,Sf9 cells have become one of the most used cell lines for 
recombinant protein expression due to their versatility and the high expression levels that can 
be achieved.  
For this work, the Sf9 recombinant baculovirus expression system was successfully 
used to induce the virus-mediated delivery of foreign proteins into Sf9 cells in an efficient and 
relatively simple expression system. Effective functional coupling of the PAR1 to Sf9 
signalling apparatus was demonstrated through Ca
2+
 assaying, and modulation of various 
signalling components provided insight into the downstream mediators of the Ca
2+
 
mobilization following stimulation with PAR1-AP in the rPAR1-Sf9 cells. 
4.1 Sf9-Baculovirus expression system 
The findings of this study confirm the successful expression of PAR1 in Sf9 cells using 
the baculovirus expression system.  
Sf9 cells have been extensively used for exogenous protein expression and have been 
studied for this purpose. Exogenous receptors expressed using this cell system yield GPCRs 
with similar post-translational modifications and comparable pharmacology to native 
mammalian proteins, with differences mainly noted in N-glycosylation [75].  
Sf9 cells possess one G-protein form of Gαi, and both Gαq and Gαs-like proteins, as 
well as PLC and AC [40].  Only Sf9 Gαq, and Gαs have been shown to be activated by 
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exogenous receptors expressed using the Sf9-recombinant baculovirus system, Gαi does not 
typically couple with most mammalian receptors [76]. 
There are some limitations to this expression system. Sf9 cells lack the ability to fully 
glycosylate proteins. Indeed, rPAR1 expressed in this cell system yielded a receptor with 
slightly lower molecular mass than that seen in mammalian cells [75].  
While endogenous receptors of Sf9 do not interfere with exogenous mammalian 
receptors, receptor densities, relatively limited availability due to low levels of endogenous G-
protein and receptor/G-protein stoichiometry may influence functional coupling [70].  
The baculovirus expression system uses a genetically modified baculovirus whereby 
the exogenous protein gene is inserted distal to the polyhedrin promoter. The pathological 
processes inherent to the use of recombinant baculovirus can be limitations to the use of this 
system. For instance, one disadvantage of polyhedrin promoter mediated recombinant 
baculovirus use is that the polyhedrin promoter is expressed late in the infection cycle, when 
cells start to lyse [75].    
 While reduced viability could be expected as a consequence of baculovirus infection, 
assays which were conducted with recombinant-PAR1 and wild-type baculovirus 
demonstrated that only recombinant baculovirus infected Sf9 cells tended to respond poorly to 
octopamine as infection progressed.  The results obtained suggest that the pathological state 
does not contribute to the attenuation of the Ca
2+
 response in infected Sf9 cells as was 
previously suggested [75], but that either the expression of exogenous receptor, competitive 
coupling of exogenous G-protein coupled rPAR1 and endogenous octopamine receptor, or the 
localization of rPAR1 on the cell membrane interfere with the octopamine receptor activation 
of a Ca
2+
 response.  
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Altogether it was established that although the octopamine response in Sf9 cells was a 
reliable viability test using microspectrofluorescence, qualitative, as opposed to quantitative 
differences in the Ca
2+
 fluxes should be noted.  Optimal Sf9 cell functionality was determined 
to be between 25 and 48 hours following infection with recombinant baculovirus.  
The rPAR1-Sf9 system presented several challenges throughout this study.  In addition 
to those discussed above, the baculovirus-Sf9 cell system proved to have several other 
limitations.  For instance, the system was non-functional during summer months (June, July 
and August) for unknown reasons. While cell cultures and infection with recombinant 
baculovirus were performed in a controlled environment throughout the year, it was difficult 
to consistently prove the viability of cells during summer months. This system was very 
sensitive to minor fluctuations in seasonal changes, humidity, fungus and bacterial 
contamination, a finding supported by other groups [40].   
Recent recommendations include the use of single-use polycarbonate Erlenmeyer 
bottles for cell propagation [75], however such a recommendation is relatively new.  Experts 
within the Biotechnology Research Institute were consulted and staff was instructed to re-
initiate cell cultures periodically, and maintain them between 6 and 65 passages. This proved 
to be an additional source of delay in the study.  
A possibility for future study would be to elaborate a stably transformed cell line where 
no pathological process and no cell lysis would occur [77]. 
4.2 Effective coupling of rPAR1 and modulation of response in Sf9 cells 
The basis of PAR1 activation by thrombin through the generation of a tethered ligand 
has implications with regard to the kinetics and magnitude of cellular response.  Dose-
dependent responses to thrombin have been demonstrated [78], but given that a single 
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thrombin molecule can cleave and activate numerous receptors, it may be possible that given 
enough time, one single molecule could cleave enough receptors to induce a response of 
greater magnitude.   
Once cleaved and activated by thrombin, PAR1 undergoes PKC-dependent [45, 79, 80] 
and PKC-independent, G-protein receptor kinase-dependent phosphorylation at its C-terminal 
Ser and Thr residues in order to inactivate the receptor [4]. Synthetic peptides corresponding 
to a five amino acid peptide sequence capable of activating the receptor and its downstream 
signalling cascades have been shown to prolong the activity of PAR1 [81].  The shortest 
peptide sequence shown to activate PAR1 corresponds to Ser-Phe-Leu-Leu-Arg and is known 
as PAR1-AP.  Receptor activation is quickly followed by its phosphorylation and lysosomal 
sequestration. Lysosomal degradation is reserved to a portion of activated PAR1 while some 
receptors return to the cell surface [79] where they remain inactive.   
Resensitization to thrombin depends on a pool of naive receptors located intracellularly 
which have been defined in a number of cell types [4, 9].  Due to the irreversible nature of 
thrombin activation of the receptor, PAR1-AP was selected as the preferred agonist.  This 
peptide sequence binds reversibly to the receptor’s active site and dissociation allows PAR1 to 
remain functional [19].    
For the current work, the use of microspectrofluorescence allowed for the study of the 
Ca
2+
 signalling pathway activated through exogenous receptor expression in Sf9 cells. Figure 
24 presents a schematic summary of the findings from our study of rPAR1 expressed using the 
Sf9-recombinant baculovirus system.   
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Figure 24: Ca
2+ 
signal modulation in rPAR1-Sf9.  Inhibitors and signal modulators used to 
determine the components which affect the [Ca
2+
]i signal in rPAR1 expressing Sf9 cells are 
schematically represented. Red text indicates an inhibitory function while green text is 
indicative of stimulatory function. SOCE represents the system of store-operated calcium 
entry including the translocation of STIM-1 to the puncta and activation of Orai-1 channels (as 
described in section 1.3.2 and discussed below).   
While previous studies suggested the lack of a thrombin cleavage site in rPAR1-Sf9 
[81], similar to work conducted by Chen & al [82], the current work demonstrated the 
successful expression of a functionally coupled rPAR1 which could be activated by both 
thrombin and PAR1-AP. Assays using confocal microscopy demonstrated that receptors were 
located mainly at the cell surface of PAR1-Sf9 cells.  
Although Sf9 cells are known to possess a number of signal transduction components 
including Gαq, i, s, o as well as PLC and AC, the technique used in this study is limited to 
studying the impact of modulators exclusively on the mobilization of intracellular Ca
2+
.  Since 
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PAR1 has not been shown to couple to αo in mammalian cells [9], coupling to this G-protein 
was not explored as there would be limited clinical relevance .  
In mammalian cells PAR1 couples to α12/13 [9].  However that signal pathway is not 
known to have any effect on [Ca
2+
]i, so it was determined that the most likely G-protein 
subunits involved in generating a Ca
2+
 signal would be αq and αi/z. 
rPAR1 coupling to Gαq is the prerequisite for activation of the PLC (PLC signalling 
cascade and subsequent release of Ca
2+
 from intracellular pools [83], such as the ER. In this 
work, D-609 [73] was used to determine what role PLC played in the initial [Ca2+]i surge 
resulting from PAR1-AP addition.  It was found that the inhibition of PLCβ by D-609 did not 
affect the rPAR1-Sf9 cell’s release of Ca2+ from intracellular storage sites in response to 
PAR1-AP. These results could suggest that insect cell PLCβ is not sensitive to D-609. 
Subsequent interference with downstream modulators was more revealing in that it 
could help determine whether modulation of the PLC signalling cascade further downstream 
could better define the role of this pathway.  
It is known that activation of PLC leads to the hydrolysis of PIP2 into IP3 and DAG.  
DAG then leads to activation of PKC. Inhibition of PKC by bisindolylmaleimide [43] 
prevented the action of this effector mechanism, prolonging PAR1 receptor mediated activity 
[45]. Assays conducted as part of this work, in Ca
2+
 free medium, demonstrated that PAR1-AP 
could continue to induce the first phase of the Ca
2+
 response following incubation with 
bisindolylmaleimide. Furthermore, PAR1-AP addition to rPAR1-Sf9 cells treated with 
bisindolylmaleimide in the presence of extracellular calcium caused oscillations which may be 
indicative of continued receptor activation brought on by a lack of PKC which interferes with 
resequestration of Ca
2+
 in the intracellular stores.  
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Activation of PKC with PDBu [44, 45] enhances the phosphorylation of PAR1, thereby 
accelerating inactivation of the receptor and inhibiting the Ca
2+
 response.   
Taken together, the findings from this work indicate a critical role for this DAG-PKC 
pathway in PAR1. Therefore, in rPAR1-Sf9, PKC activation seems to be an integral 
component of the plateau phase of the PAR1-AP Ca
2+
 response, as well as the resequestration 
of Ca
2+
. 
Since evidence indicates that Sf9 cells possess both Gαq as well as PLCβ [75], the fact 
that D-609 did not affect the rPAR1-Sf9’s ability to activate a Ca2+ signal may point to 
limitations in this expression system. Previous studies have shown that PAR1 couples to 
endogenous Gαq in Sf9 cells [26], but insect Gαq is obviously not the physiological coupling 
partner of mammalian PAR1.  Therefore, the impact of insect Gαq on receptor pharmacology 
cannot be excluded.  It is possible that the release of Ca
2+
 from the storage sites is mainly 
mediated by another intracellular messenger in rPAR1-Sf9 cells, or simply that the PLC  in 
insect cells is insensitive to D-609.   
In mammalian cells, PAR1 is also known to couple to the Gαi pathway. The activation 
of Gαi is known to inhibit AC and subsequent PKA [26].  The Gi-PKA pathway is involved in 
downstream MAPK activation in mammalian cell studies, however, limited studies have been 
conducted to study the intermediate steps in the PKA pathway in Sf9 cells [40].  Furthermore, 
insect cell Gαi does not couple to most mammalian GPCR [40].   
In the current study, PKA inhibition with H-89 was used to explore the role of PKA as 
a contributor to the Ca
2+
 signal.  The results obtained with this agent, i.e., the suppression of a 
Ca
2+ 
flux in Ca
2+
 -free medium, suggest that PKA is critical to the Ca
2+
 mobilization from 
intracellular storage sites. H-89 was initially thought to inhibit PKA by competitively binding 
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to the ATP binding site of this kinase, thereby interfering with its phosphorylation and 
activation. However, H-89 has recently been found to also interfere with K
+
 and Ca
2+
 channels 
[37], although how it does so remains unclear, and no such results have been detected in Sf9 
cells.  H-89 has also been shown to affect other PKA-dependent factors, including the Ca
2+
-
ATPase, an essential component to Ca
2+
 storage in the ER [84]. 
 In the rPAR1-Sf9 system, it is possible that H-89 was strictly acting on PKA, 
suggesting that the PKA-cAMP pathway is a critical cofactor in the release of Ca
2+
 from the 
ER, primarily in a Ca
2+
 deficient environment where intracellular storage sites are the only 
source of Ca
2+
.  
The uncertainty with regards to the exact role H-89 exerts in the rPAR1-Sf9 system 
makes it impossible to determine how H-89 acts in Sf9 cells and whether PKA has a definite 
role in the Ca
2+
 signal in rPAR1-Sf9. In the event that H-89 interferes directly with the Ca
2+
 
channels [37], this would be highly revealing as to the critical role of Ca
2+
 channels in 
regulating the release of Ca
2+
 from the ER, as suggested by the results in Ca
2+
-free 
environment, as well as being further supported by the findings with D-600. 
D-600 is a lipophilic calcium-channel blocker which can exert its activity 
intracellularly, as well as extracellularly.  In this work, D-600 could abolish the PAR1-AP 
induced response in a Ca
2+
 free environment. The reason for this is unclear but may suggest 
that D-600’s action on intracellular Ca2+ channel blockade prevented Ca2+ release from 
intracellular storage sites. These findings may, alternately, suggest that functional Ca
2+
 
channels are required for the PAR1-AP response to occur.  
The ability of D-600 to induce Ca
2+
 oscillations in calcium-rich media suggests that 
this lipophilic agent also interfered with Ca
2+
 resequestration following the plateau phase. 
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The interference by D-600, therefore, may have occurred in both the efflux of Ca
2+
 from 
storage sites into the cytosolic space and the resequestration of Ca
2+
 into the ER. 
4.3 Store-operated Ca
2+
 entry 
While previous studies have demonstrated the successful expression and functional 
coupling of PAR1 in Sf9 cells [82], this study is the first demonstration of intracellular 
Ca
2+
signalling in response to PAR1 activating peptides in single PAR1 expressing Sf9 cells.   
Sf9 cells are known to have the molecular machinery necessary for receptor-mediated 
Ca
2+
 signalling.  They possess effective G-protein coupled Ca
2+
 signalling which accesses 
thapsigargin-sensitive Ca
2+
 stores [40].   
Thapsigargin promotes Ca
2+
-store depletion through its inhibition of Ca
2+
-ATPase 
[70].  Consistent with previous studies, thapsigargin acted to mobilize the Ca
2+
 from the ER, 
causing a small transient increase in the [Ca
2+
]i [85].  Furthermore, in this work, depletion of 
the Ca
2+
 from the ER with thapsigargin eliminated the response to PAR1-AP.   
On the other hand, inhibition of the Ca
2+
 release from intracellular sequestration sites, 
with TMB-8, inhibited the PAR1-AP effect in 50% of the rPAR1 expressing cells tested.  The 
effect of TMB-8 was most notable in the absence of extracellular Ca
2+
 where 100% of the 
cells tested showed inhibition of the calcium transient produced by PAR1-AP. The reason for 
this inconsistent effect is not entirely clear.  However, it could suggest that while in 0GSM the 
Ca
2+
 surge is only due to release of Ca
2+
 from storage sites, in 2.8GSM, the source of Ca
2+
 is a 
combination of release from intracellular sites and entry from the extracellular space.    
Altogether, these results suggest that the primary phase of the PAR1-AP-induced 
[Ca
2+
]i  response in rPAR1-Sf9 cells is dependent on the release of Ca
2+
 from intracellular 
storage sites following the addition of PAR1-AP and can be inhibited by either depleting the 
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Ca
2+ 
storage site with thapsigargin or preventing the release of Ca
2+
 from these sites with 
TMB-8.   
Interestingly, assays conducted with the lipophilic voltage-dependent Ca
2+
 channel 
blocker D-600 could add information regarding the contribution of extracellular Ca
2+
 to the 
primary phase of the PAR1-AP response.  D-600 demonstrated that functional Ca
2+
 channels 
are required in order for the first phase of the PAR1-AP response to be produced.  
When taken altogether, results obtained in calcium-rich and calcium-free media 
demonstrated that the PAR1-AP response possesses two phases to the Ca
2+
 flux. The results 
suggest an initial release of Ca
2+
 from internal stores and a subsequent influx of Ca
2+
 
dependent on the initial release.   
Currently available evidence suggests that Sf9 cells possess endogenous voltage-gated 
Ca
2+
 channels [40, 62], as well as a component of calcium entry known as store-operated 
calcium entry (SOCE) [70].  
As the name implies, the activation of store-operated calcium channels (SOC) occurs 
after the initial release of Ca
2+
 from intracellular stores, thus following Ca
2+
 store depletion 
[39].  Ca
2+
 stores are able to transmit store depletion to the plasma membrane and the 
extracellular space, leading to the activation of a Ca
2+
 entry system. This transmission of 
information related to Ca
2+
 storage levels is thought to occur through stromal interacting 
molecule-1 (STIM-1) [38].  STIM-1 resides on the luminal surface of the ER and serves as a 
detector of low levels of Ca
2+
.  This causes the translocation of STIM-1 to the ER-plasma 
membrane junctions, known as puncta.  Once translocated to the puncta, STIM-1 interacts 
with store operated Ca
2+
 (SOC) channels on the plasma membrane, thereby critically 
mediating their activity [39]. 
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There are two types of SOC; the first of these is the Orai-1, a Ca
2+
 -selective channel 
which functions as an L-type Ca
2+
 channel. The second type is the transient receptor potential 
(Trp) channel, a non-selective cation channel [38, 39]. 
In previous studies using cell suspensions, and conducted by microspectrofluoroscopy, 
it was concluded that the octopamine response primarily reflects Ca
2+
 release from internal 
stores [70]. A secondary influx of Ca
2+
 from the extracellular space was also detected in 
response to octopamine stimulation [70].  The current study demonstrates, for the first time, 
that an exogenous receptor expressed in Sf9 cells is able to activate SOCE.   
These findings are supported by the results obtained using both La
3+
 and nifedipine 
which eliminate the plateau phase of the PAR1-AP response in rPAR1-Sf9 cells, suggesting 
the need for Ca
2+
 entry from the extracellular space.   
The detection of a Ca
2+
 influx related to SOC channels in Sf9 cells has been very 
limited [70].  While it has previously been described  that recombinant baculovirus infection 
of Sf9 cells can induce a slight change in the membrane permeability to Ca
2+
 by activating a 
cation channel [62], later work has suggested a directly activated Ca
2+
 channel in Sf9 cells 
expressing the M5 muscarinic receptors [70] but not when expressing other exogenous 
proteins.  The reason for limited detection of SOC activity in Sf9 using recombinant 
baculovirus may also be explained in part by findings relevant to mammalian cells. 
Interestingly, studies conducted using mammalian cells have suggested that store-operated 
Ca
2+
 entry (SOCE) was only associated with a portion of the Ca
2+
 stores and contributes to the 
amplification of the peak Ca
2+
 signal above that achieved by Ca
2+
 release alone [86, 87]. 
Specifically, only a subset or fraction of the Ca
2+
 release from Ca
2+
 stores contributes to the 
translocation of STIM-1 to the puncta, and activation of SOCE [86, 88].  STIM-1 has been 
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shown to be activated when store concentration levels reach a very low threshold Ca
2+
 level 
[38].  A similar, distinct, subset of Ca
2+
 stores has been detected in Sf9 cells [70]. It is possible 
that Ca
2+
-store depletion following octopamine, or following activation of other recombinant 
receptors expressed in Sf9 cells do not drain Ca
2+
 stores enough to reach threshold levels of 
Ca
2+
 required for STIM-1 translocation and SOCE activation.  
The variable coupling ability of exogenous receptors to the Sf9 signalling apparatus 
cannot be ruled out as a potential reason for the failure to access the SOCE-specific subset of 
Ca
2+
 stores in Sf9 cells.   
In summary, the data obtained in this study suggests, for the first time, a role for a 
SOCE activation following exogenous receptor activation in Sf9 cells.  
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CONCLUSION AND FUTURE DIRECTIONS 
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 5.1 Conclusion 
The current study set out to determine whether recombinant baculovirus expression 
using Sf9 cells could effectively express functional rPAR1 capable of coupling to the Sf9 cells 
signalling apparatus.  
The study of distinct receptors in mammalian cells can be difficult for several reasons 
and can be circumvented by using the recombinant baculovirus-Sf9 signalling system.  For 
instance, mammalian cells may contain lower receptor densities than can be achieved in a 
recombinant expression system.  From a receptor activation perspective, multiple receptors or 
receptor subtypes may exist, with similar ligand binding properties [89]. Lastly, receptor 
cross-talk cannot be ruled out when trying to study receptor-mediated responses in mammalian 
cells [89-91].   
Data obtained through the current study confirms the utility of the Sf9-recombinant 
baculovirus expression system as a versatile heterologous expression system.  While some 
limitations exist, this system allowed for the selective expression of a mammalian protein 
highly similar to the native protein. rPAR1 was localized mainly at the cell surface and was 
able to maintain its native agonist specificity. 
rPAR1 was also shown to couple effectively with the insect cell signalling apparatus, 
both in response to thrombin and PAR1-AP. Receptor activation was able to produce a 
downstream signal which was studied using a variety of signal modulators and channel 
blockers.  
Signal modulators suggest a critical role for PKC in the rPAR1-Sf9 Ca
2+
 response. 
This Ca
2+
 response, measured using Fura-2, is composed of two phases.  The first 
phase of the response is mediated by PKC, and requires the presence of functional Ca
2+
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channels, particularly intracellularly, for the initial release of Ca
2+
 from Ca
2+
 stores. This 
release of Ca
2+
 from the ER is critically regulated by low levels of PKC, presumably since 
high levels of PKC may cause early phosphorylation of the PAR1 and receptor deactivation, 
as well as the phosphorylation of IP3R and Ca
2+
 channels, essentially causing them to become 
inactivated faster . 
The second phase of the Ca
2+
 response in rPAR1-Sf9 cells involves activation of store-
operated Ca
2+
 entry not previously described with PAR1 expression. 
 
5.2 Future directions 
The Sf9-baculovirus expression system is a useful expression system to study the 
expression and functional coupling of rPAR1. However, the pathological state resulting from 
infection with the baculovirus results in the questionable dependability of this expression 
system.  A stably transfected Sf9 cell line, capable of expressing a functional receptor, could 
provide a more reliable system to study receptor activation and the Sf9 cell could provide an 
isolated environment to study a selected mammalian receptor such as the rPAR1. This system 
could also be a method of choice for the study of orphan receptors, and screening of 
compound libraries. 
Ultimately, an exogenous ligand, capable of selectively activating/inactivating a 
signalling pathway, could be developed to modulate thrombin’s cell-targeted activities.   
The potential therapeutic usefulness of inhibiting PAR1 has led to the development of 
several PAR1 receptor antagonists studied for their potential in the long-term prevention of 
cardiovascular events including myocardial infarct, cardiovascular death and stroke.  
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APPENDIX 
 
Calibration of intracellular Ca
2+
 concentration 
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The calibration procedure consisted of the addition of 10µM ionomycin to a wild-type 
Sf9 cell bathing in a 10mM Ca
2+
 medium, causing the intracellular [Ca
2+
] to reach the same 
level as its surroundings. Subsequently, a 10mM EGTA solution is added to the preparation. 
The resulting chelation of calcium is demonstrated by a sharp change in the fluorescence being 
emitted. This experiment allows us to relate the observed calcium response, resulting from cell 
stimulation, to the maximal and minimal observable signal in the Sf9 cell type.  This allows us 
to draw a link between the fluorescence ratio and the quantitative change in the intracellular 
[Ca
2+
]. 
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Figure 25: Calibration of the Sf9 calcium signal. A: Individual tracings. Tracings obtained 
using dual excitation at wavelengths of 340 and 380nm for a single Sf9 cell in 10mM Ca
2+
 
solution.  The addition of 10µM ionomycin followed by 10mM EGTA in Ca
2+
-free solution 
occurred at 127 seconds and 280 seconds, respectively. B: Ratio representative of the 
calibration of the Sf9 Ca
2+
 signal. Normalized ratio F340/F380 shown is representative of 
results obtained for 3 identical experiments.   
  
 
 The maximum and minimum measurable ratio reflecting [Ca
2+
]i can be determined. 
The ratio value was used to determine the cellular response to changes in [Ca
2+
]i. 
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 Calculation of [Ca
2+
]i can be performed using the following formula based on the value 
of the ratio [92]: 
[Ca
2+
]i =Kd  (R-Rmin/Rmax-R) x F0 380/ FS 380 
where Kd represents a constant, Rmin and Rmax are the minimum and maximum observable 
Ca
2+
 ratios and F0 380/ FS 380 represents the fluorescent values in a calcium-free and calcium-
saturated solutions at 380nm wavelength.  
 The equation can be simplified by adding in the value of the constant for Kd equal to 
135mM at room temperature, and the values obtained through the calibration experiment, as 
shown on Figure 23B: 
[Ca
2+
]i = 135mM (R - 0.49/5.26 – R) x 7.33 
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